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Abstract 
Firm Y is a biopharmaceutical firm specializing in the newly emerging business sector of 
RNAi Therapeutics. Firm Y is one of a few firms aspiring to bring this potential new class of 
human therapeutics to the market. Currently, the firm has a well-established RNAi therapeutics 
delivery platform, manufacturing capabilities, a stream of strategic partnerships, and development 
stage products in its pipeline. Firm Y wants to expand its product pipeline to give it a sustainable 
competitive advantage in RNAi therapeutics and ensure long-term success in its strategy to 
develop important new human therapeutics. 
The purpose of this strategic analysis is to identify new market opportunities for Firm Y 
for expansion of its product pipeline. The analysis is based on the company’s core competency of 
RNAi product delivery to the liver using its proprietary platform, PLATFORM X. First, analyses 
were conducted on the external industry environment and Firm Y’s internal capabilities and 
situation. Second, new market opportunities were identified and assessed. Third, a number of 
criteria were used to conduct a comprehensive evaluation of potential new markets for Firm Y. 
This evaluation was based on scientific and business feasibility specific to Firm Y.  
The results of this strategic analysis indicate that Firm Y should expand its product 
pipeline in a liver diseases area. The analysis further suggests that the expansion should be in the 
area of infectious diseases. The opportunities of interest for Firm Y within the liver diseases are 
Hepatitis B and Hepatitis C. The analysis also indicates Hepatocellular Carcinoma as a good next 
opportunity. Overall, with expansion of its product pipeline, Firm Y will show long-term growth 
potential for its shareholders and provide increased confidence in its ability to continue as a 
successful firm.  
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Glossary 
D
A – stands for deoxyribonucleic acid; it is a molecule that makes up genes; it consists of 
nucleotides 
 
EFFICACY – refers to the therapeutic effect of medicines in treating the intended disease 
 
EFFECTIVE
ESS – a term referring to both safety and efficacy of the therapeutics 
 
GE
E – hereditary unit that consists of nucleic acids that can be DNA or RNA; it is part of a 
genome, organism’s hereditary material 
 

UCLEIC ACIDS – molecules made of nucleotides 
 

UCLEOTIDE – building blocks of DNA and RNA; there are five of them: three common to 
both DNA and RNA (adenine – A, cytosine - C and guanine – G) and one specific to DNA 
(thymine – T), and one specific to RNA (uracil – U) 
 
OLIGO
UCLEOTIDE – a short nucleic acid molecule consisting of twenty or less nucleotides; 
oligonucleotides form basis for RNAi therapeutics 
 
R
A – stands for ribonucleic acid; a biological molecule crucial for the protein synthesis; it 
consists of nucleotides 
 
R
Ai therapeutics – for this analysis refers to a potential class of human therapeutics 
 
R
Ai Therapeutics – refers to the RNAi Therapeutics sector within the biotechnology sector 
 
SAFETY – how safe therapeutics is for patients 
 
siR
A – small interfering RNA, a one type of oligonucleotides, it is approximately twenty 
nucleotides in length; it is a specific sequence corresponding to a target gene; results in triggering 
a mechanism to “silence” specific gene that results in no or reduced amount of protein made 
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Chapter 1: I
TRODUCTIO
 
1.1 Purpose of the Analysis 
Firm Y is a biopharmaceutical firm that specializes in the delivery and development of 
ribonucleic acid interference (RNAi) therapeutics. Firm Y has two lines of business: (1) RNAi 
delivery technology, and (2) product development. PLATFORM X is a leading delivery 
technology to deliver RNAi therapeutics to specific target sites within the body. Currently, Firm 
Y has a couple of development stage products in the product pipeline. Firm Y is publicly traded 
on the TSX.  
Firm Y has numerous collaborations with leading pharmaceutical firms. These 
collaborations allow it to maximize the potential of PLATFORM X. Firm Y’s partnering goal is 
to help its collaborators develop successful product candidates that utilize the PLATFORM X. 
This line of business has allowed Firm Y to generate revenues that cover its operational costs and 
allow it to pursue its own drug development program. 
 In order to grow and succeed in returning value to its shareholders, Firm Y would like to 
expand its internal product pipeline. The firm needs to identify new market opportunities in order 
to find the most profitable opportunities that build on its current core competencies. The purpose 
of this strategic analysis is to identify and evaluate new market opportunities for Firm Y. 
Recommendations for the best new market opportunities will be provided, considering the firm`s 
capabilities and potential future strategies for PLATFORM X. 
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1.2 Outline of the Analysis 
To reach a final set of recommendations on the strategic market opportunities for Firm Y, 
first, I analyze the external environment in which Firm Y operates. Second, I analyze the 
organizational capabilities of Firm Y. Third, I describe the approach and methodology that led to 
identification of new potential markets for this analysis. Fourth, I provide information and 
analysis concerning the newly identified market opportunities specific to Firm Y. Finally, I 
conclude with a complete evaluation of potential new markets and a set of recommendations for 
Firm Y. 
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Chapter 2: A
 A
ALYSIS OF FIRM Y’S EXTER
AL 
E
VIRO
ME
T 
2.1 An Introduction to Firm Y’s External Environment 
In this chapter, I analyze the external environment in which Firm Y operates. I start with 
a broader industry group that consists of the Global Pharmaceuticals, Biotechnology and related 
Life Sciences industry (Datamonitor, 2010a). I narrow in on the biotechnology sector within the 
broader industry group. Next, I look at the business models and supply chain relevant to Firm Y. 
First, I discuss the emerging business models of the firms within Firm Y’s competitive 
environment. Second, I discuss Firm Y’s value chain, the drug development process (DDP). Then 
I focus on a specific sector within Biotechnology, RNAi Therapeutics. This sector is still 
embryonic and shows great promise for providing breakthroughs for treatment of human disease. 
Firm Y specializes in this sector. For the RNAi Therapeutics sector, I use the ``Five Forces 
Model`` (Porter, 2008) to analyze the competitive landscape.  
2.2 The Industry Group: An Analysis of the Global 
Pharmaceutical, Biotechnology and Life Sciences 
(GPBLS) Industry  
 
In this section, I analyze the broader industry group using the Datamonitor definition. 
The industry group includes the Global Pharmaceuticals, Biotechnology and Life Sciences 
industry (Datamonitor, 2010a). From now on, I refer to it as “the industry group”.  
The definition of each market within the industry group is defined according to the 
Datamonitor report. The industry consists of three markets. The pharmaceuticals market includes 
only therapeutic drugs for human use (Datamonitor, 2010a). The biotechnology market includes 
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both medical and non-medical biotechnology products developed, manufactured or marketed by 
biotechnology firms (Datamonitor, 2010a). The life and sciences market is limited to firms 
providing tools and services to the pharmaceuticals and biotechnology markets (Datamonitor, 
2010). 
While the industry group faced uncertain times during the 2008 to 2010 global financial 
crisis, it still was able to grow (Datamonitor, 2010a). In 2009, the industry generated revenue of 
US $1,071.1 billion representing a growth rate of 5.3% (Datamonitor, 2010a). By 2014, the 
revenue for the industry group is expected to reach US $1,402.4 billion (Datamonitor, 2010a).  
The Americas region leads the geographic market share with 50.5% while Europe has 
20.7%, Asia-Pacific 18.2%, and the rest of the world represents 5.7% of the market share 
(Datamonitor, 2010a). Pfizer is the leading firm with 4.7% market share followed by Roche with 
4.2%, Sanofi-Aventis with 3.8% and Novartis with 3.6% (Datamonitor, 2010a).  
The pharmaceuticals market segment represents 75.7%, biotechnology 22.7% and the life 
science tools and services 1.7% of the total industry group (Datamonitor, 2010a). The 
competitive landscape can be summarized as follows: buyer power for the industry group is 
moderate, the threat of substitutes is low, supplier power is moderate, the threat of entry is 
moderate, and rivalry is moderate (Datamonitor, 2010a).  
The industry group spends heavily on research and development (R&D). Once a drug is 
successfully developed and brought to market, profits for the firm can be high. The 
pharmaceuticals market is very profitable, with a 17% profit margin (Datamonitor, 2010a). 
However, biotechnology’s innovative R&D capabilities are becoming more important to the 
large pharmaceutical (Big Pharma) firms and their pipelines. These pharmaceutical firms are 
turning to biotechnology and to emerging biopharmaceutical firms for innovative new 
technologies and approaches to novel therapies. In the next section, I analyze the global 
Biotechnology sector.  
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2.3 The Biotechnology Sector: An Important Source of 
Innovation 
 
The biotechnology market refers to the products arising from the biotechnology research. 
One useful definition of the biotechnology industry is that it “is the application of science and 
technology to living organisms as well as parts, products and models thereof, to alter living or 
non-living materials for the production of knowledge and biotechnology products and services” 
(IBIS World, 2010, pg.3).  
The biotechnology industry is now approximately thirty years old. In 2009, the estimated 
revenue for the global biotechnology industry was US $200.9 billion representing a growth rate 
of 5.3% (Datamonitor, 2010b). The biotechnology sector revenue accounts for approximately 
20% of the revenue of the industry group reported above. The growth rate of the biotechnology 
sector is currently the same as the broader industry group. However, by 2014, revenue for this 
sector is expected to reach US $318.4 billion (Datamonitor, 2010b). Compared to 2009, this is an 
increase of 58.5% (Datamonitor, 2010b) and is significantly higher than the estimated 31% for 
the broader industry group.  
There are several reasons for this higher growth rate. First, the biotechnology sector is 
mature and growing. Firms that spent years developing products are finally becoming profitable. 
Second, biotechnology products in the therapeutics sector have potential for a longer period of 
exclusivity for patent protection (Trusheim, 2010). As such, they can be more profitable for a 
longer time. Third, the field of bio-generics is still in its infancy. Big Pharma is currently 
struggling with competition from generics. In 2000, generics had 49% of the pharmaceutical 
market share. In 2009, generics had 74% of the market share (PhRMA, 2010). As such, generics 
represent a significant threat to Big Pharma`s revenues and profits.  
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Overall, the biotechnology sector is very innovative, especially when it comes to specific 
diseases. The biotechnology sector focuses on addressing areas of high-unmet needs such as 
orphan diseases, which also meet the needs of Big Pharma to fill their diminishing pipelines. Big 
Pharma`s strategy is to invest in these biotechnology firms as a supplement or replacement to in-
house R&D. As a result, there is an increasing trend of partnerships, mergers and/or acquisitions 
between Big Pharma and biotechnology firms.  
For the biotechnology sector, the Americas region represents a 48.4% market share, 
Asia-Pacific 26.4% and Europe 25.2% (Datamonitor, 2010b). Datamonitor lists Merck KGaA, 
Novartis AG, Pfizer Inc. and Astra Zeneca PLC as the leading firms in these markets. However, 
that all of these firms are Big Pharma suggests that biotechnology-based products are a 
significant part of the Big Pharma investments in the biotechnology sector. Consequently, the 
biotechnology sector can be considered well established and growing.  
However, the IBIS World report on the Global Biotechnology Industry reports on “true” 
leading biotechnology firms. What is meant by “true” is that these firms started as biotechnology 
firms and were pioneers that helped establish the biotechnology sector. In 2010, the market share 
distribution of these major biotechnology players is: (1) Amgen Inc. with 9.5%, (2) Genentech, 
Inc. with 9.0%, (3) Syngenta AG with 5.5%, (4) Merck KGaA with 4.5%, (5) Monsanto Firm 
with 4.5%, (6) Genzyme Corporation with 2%, and (7) Biogen Idec Inc. with 2% (IBIS World, 
2010).  
The market segmentation for the global biotechnology industry is divided into five 
categories. The medical/healthcare category has 66.2% of the market share, service provider 
13.9%, food and agriculture 11.5%, environment and industrial processing 4.2%, and technology 
service 4.1% (Datamonitor, 2010b). Note that the medical/healthcare sector identified as most 
relevant to Firm Y leads the market share.  
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For the global biotechnology industry, the competitive landscape can be summarized as 
follows: buyer power is moderate, the threat of substitutes is moderate, supplier power is 
moderate, the threat of entry is low, and rivalry is moderate (Datamonitor, 2010b). However, as 
the global biotechnology industry includes markets not relevant to Firm Y, such as the food and 
agriculture market segment, the analysis that follows will focus exclusively on the RNAi 
Therapeutics sector specific to Firm Y. 
Overall, the biotechnology industry has two key characteristics: (1) the need for a strong 
intellectual property (IP) to ensure firm survival; and (2) very strict government regulations for 
the development, manufacturing and marketing of products. These two key characteristics 
influence the entry and rivalry within the biotechnology sector relevant to Firm Y.  
2.4 The Changing Biotechnology Business Models 
2.4.1 An Introduction to Changing Business Models 
A business model serves a firm as a basis of how to generate revenues and profits (Grant, 
2008). However, a firm still needs a strategy of how it will create (develop), deliver (make 
revenues and profits) and capture (sustainable competitive advantage) value proposed in the 
business model (Grant, 2008). This strategy allows the firm to prosper and to display a long-term 
growth potential while creating value for its shareholders.  
Today, advances in science and technology create novel therapeutic approaches. They 
also create new opportunities for existing and emerging firms. Hence, the changing landscape 
calls for more flexible and adaptable business models, in which for example, firms are more 
creative at reducing fixed costs by adopting different business models to enhance profits while 
creating additional value for the firm and its shareholders.  
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The changing landscape is important for Big Pharma and biotechnology firms. In 
particular, the biotechnology sector is in need of more flexible and creative business models. 
First, biotechnology firms that only develop therapeutics, remain unprofitable for most of their 
lifecycle. The reason for this is a long and costly drug development process (DDP). It takes many 
years to bring a product to the market, and many products never make it to the market. Hence, it 
takes years of investment to develop such therapeutics before any revenues or profits are made. 
The scarcity of investments, especially during the global financial crisis made it difficult for 
biotechnology firms to raise the needed capital.  
Second, the biotechnology sector is a high-risk and has a high-failure rate. Big Pharma 
can afford to have numerous products in its pipeline, leading to more diversified portfolios. In 
addition, it increases the chance that some products will survive and make it to the market. These 
successful products are expected to offset the cost of products that fail. However, a small 
biotechnology firm with limited resources and capabilities often starts with only one product in 
its pipeline. This is a very high-risk proposition as the firm can either make it with that one 
product, or cease to exist. Hence, the call for new business models in the biotechnology sector. 
Current business models are more flexible and variable. There are more service and tool firms 
emerging as well that, for example, attempt to create value from scientific and technological 
advances in fields such as bioinformatics. 
For the purpose of this analysis, I discuss different business models relevant to Firm Y 
and its external environment. Figure 1 is adapted from and based on information from Konde 
(2009). Figure 1 shows the business models and how they fit within the supply chain.  
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Figure 1: Business Models and Supply Chain 
 
Source: Adapted from Figure 1 in Konde (2009). 
The supply chain is simplified for the purpose of this analysis. It is based on the value 
chain of the drug development process (DDP) that consists of basic research, product 
development, manufacturing, and marketing and sales. There are four different business models: 
(1) Platform, (2) Product, (3) Hybrid and (4) Vertical (Konde, 2009). Next, I describe each of 
these business models.  
2.4.2 Product Business Model 
The product business model of biotechnology firms focuses on developing a product. For 
example, a vaccine or a cancer drug is developed. Many firms in the early days of the 
biotechnology industry started with this type of business model. However, due to the high-risk, 
high-failure rate, high costs and complexities of therapeutic product development, many firms 
failed with this model. Only a few firms like Amgen managed to survive. Therefore, this business 
model required a change. The main focus of the change was to reduce fixed costs as much as 
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possible. One strategy was the formation of more public-private partnerships. This allowed firms 
to utilize the resources and capabilities of the public institutions like universities for the basic 
research stage in the supply chain. The second strategy was to remain virtual as long as possible. 
This approach allowed firms to make minimal infrastructure investments. Hence, many activities 
would be out-sourced to focus on advancing the product to the next stage of the development 
rather than building an organization.  
2.4.3 Platform Business Model 
Some biotechnology firms develop a strong technology platform around which they build 
IP and patents, and then out-licence this technology to other biotechnology firms and Big 
Pharma. As a result, these firms are able to generate revenues at an early stage of the firm. There 
are different options with the platform business model as well. For example, the emergence of 
bioinformatics led to new commercial opportunities for tools or service type firms. Other 
platform firms resemble Firm Y. They develop drug delivery technologies for different types of 
therapeutics.  
2.4.4 Hybrid Business Model 
The hybrid business model is a combination of product and platform business models. In 
the hybrid model, firms usually use proprietary technology platform to generate revenues to 
offset costs of their operations. This revenue allows firms to invest in R&D at an early stage to 
improve their proprietary platform. Alternatively, it allows firms to enter a new line of business 
and start developing other products. Overall, the firm generates revenue while improving its 
current technology and developing a new line of products. Firm Y utilizes this business model.  
In utilizing this hybrid model, firms avoid the dependency on limited external financing 
options, and, therefore, have less liability and are more liquid. The hybrid business model is 
becoming more important in the biotechnology sector as it prevents the high-failure rate problem 
 11 
 
of the product business models, and allows firms to generate revenues early on to support the 
high R&D costs of drug development.  
2.4.5 Vertical Integration Business Model 
Fully Integrated Biotechnology Company (FIBCO) is a business model that encompasses 
full vertical integration along the supply chain. A few major biotechnology firms like Amgen are 
FIBCO. Big Pharma firms are vertically integrated as well. Firms like Novartis, Pfizer, and 
Merck have organizational capabilities to take the drug from the discovery stage to the market. 
However, due to sector’s fast changing landscape, the vertical business model is changing as 
well. Big Pharma is turning to emerging markets such as BRIC (Brazil, Russia, India and China) 
countries to out-source some aspects of their business. In addition, Big Pharma and FIBCO invest 
in emerging, new product, platform and hybrid biotechnology firms to enable them to add 
innovative products developed by the biotechnology sector to their portfolios. This further 
increases the industry trend of early stage partnerships, mergers and acquisitions.  
2.4.6 Adding Value via Partnerships 
Partnerships are important strategic choice of many firms: emerging biotechnology firms, 
FIBCO and Big Pharma. Newly emerging firms can adopt the strategy of specializing in one area 
of the supply chain in order to build value for a future acquisition or merger. In addition, 
scientific and technological advances add to the changing trends for partnerships. Advances in 
molecular biology and genetics encourage firms to build more collaborative research partnerships 
early on with public institutions such as universities. These collaborations can lead to validated 
gene targets as potential future therapeutics for a disease. As a result, the private and public 
efforts are maximized. Firms save costs of the early research stage of the DDP while public funds 
and research aid the development of better therapeutics for patients.  
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Partnerships also create value between private companies. A product development firm 
can strategically assess which products to add to its pipeline. This creates value and attractiveness 
of that firm for a potential future buyer. For example, a firm developing a product finds a Big 
Pharma or another biotechnology firm as a potential partner. As a result, this leads to either an 
acquisition or a merger, co-development of the product, or assistance with commercialization of 
the product. All these partnership options serve the purpose of benefiting both firms and their 
shareholders.  
2.4.7 Summary: From Business Models to the Value Chain 
As the competitive landscape changes, so do business models. Firms are not only 
innovative with their scientific and technological platforms and products, but with their business 
models as well. The adaptability of the firm to its internal and external environment is vital for its 
survival. This is especially important in an IP driven and highly complex and regulated industry 
such as biotechnology. The fast changing competitive landscape stimulated the emergence of 
more flexible and adaptable business models such as the product, platform, hybrid of the product-
platform and integrated business models.  
In addition, through participating in out-sourcing, mergers and acquisitions, the industry 
is shifting towards more global and collaborative public and private partnerships in established 
and emerging economies. Even though the human therapeutics sector is challenging and 
complex, it is driven by passion for research to improve human lives. In the next section, I look at 
this challenging and long process of bringing a human therapeutics from the lab to the market. 
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2.5 The Value Chain: The Drug Development Process (DDP) 
2.5.1 An Introduction to the Drug Development Process  
In this section, I describe the value chain of the Drug Development Process (DDP). The 
regulation and complexity is justifiable, because the industry is dealing with human lives and 
health. While the main stages in the process have remained constant over time, the process is 
becoming more complex and costly as advancements in science and technology arise. In the next 
sections, I describe the regulatory body that oversees the DDP, and then I outline each stage of 
the DDP process to conclude with a brief note on current complexities and costs.  
2.5.2 Regulatory Aspects of the Drug Development Process  
Which regulatory bodies oversee this highly regulated industry? In Canada, it is Health 
Canada. In the United States, it is the Food and Drug Administration (FDA). In Europe, it is the 
European Medicines Agency (EMEA) and the National Health Authorities in EU countries 
(Mancini, 2010). As we are in era of globalization and consolidation, the regulatory environment 
is no different. There is a need for harmonization to make it easier for firms to obtain approvals 
in more than one country. There is such an initiative to harmonize the regulatory process in the 
US, EU and Japan called The International Conference on Harmonisation of Technical 
Requirements for Registration of Pharmaceuticals for Human Use (ICH) (Mancini, 2010).  
Overall, the main goal of regulatory bodies is to ensure safety, efficacy, and quality of 
the new therapeutic products in order to ensure improvement and protection of public health 
(Mancini, 2010). For the purpose of this analysis, I refer to stages typical for the DDP under the 
US FDA.  
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2.5.3 Main Stages in the DDP 
There are three main stages in the DDP. Figure 2 shows these different phases of the 
DDP. 
Figure 2: The Standard Drug Development Process (DDP) in the US 
 
 
Source: Adapted from MedicineandBiotech (2004) and based on information from PhRMA report 
(2010). 
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Drug Application (NDA) document is submitted, reviewed and approved by the FDA. The third 
stage is the market entry and commercialization of the drug. Once the drug is on the market, there 
might be phase IV clinical trials to conduct post-approval surveys. In the next sections, I describe 
each stage in more detail.  
2.5.4 A Closer Look: A Product’s Journey from Research to 
Development to Market 
 
2.5.4.1 The Research Stage 
The Research stage takes from three to six years to complete. A discovery stage starts 
with understanding a disease and looking for a potential target. In the case of a small molecule 
drug, this stage starts with 5,000 to 10,000 candidate compounds (PhRMA, 2010). In the research 
stage, there are fewer candidates, which progress to preclinical studies in animals to ensure 
safety. At the end of this stage, the IND is filed, and when approved, a Phase I clinical trial can 
be initiated. As Figure 2 depicts, at this stage there are approximately 250 candidates in a 
pipeline.  
2.5.4.2 The Development Stage 
The Development stage consists of three human clinical trials: Phase I, Phase II and 
Phase III. These are described in more detail in the following sections.  
2.5.4.2.1 Phase I Clinical Trials 
Next is the development stage that starts with the Phase I human clinical trials once the 
IND is approved by the FDA. In Phase I, the trial usually has 20 to 100 healthy volunteers and 
the safety of the drug is extensively tested. The trial might take a year or longer to complete 
(PhRMA, 2010). Safety is tested by administering high doses of the drug so that toxicities and 
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safety ranges are fully explored (Tomke, 1998). However, this phase does not typically provide 
information on the efficacy of the drug. 
2.5.4.2.2 Phase II Clinical Trials 
Phase II clinical trials are designed to test the efficacy of the drug. Efficacy is determined 
by testing how well the drug treats the disease for which it is being developed. The Phase II 
clinical trials consist of 100 to 500 volunteers (PhRMA, 2010). These trials are usually “blinded” 
and utilize controls. This means that a portion of the patients is taking placebo and the doctors 
themselves do not know which patients receive placebo and which do not (Tomke, 1998). This 
phase usually takes about two years. 
2.5.4.2.3 Phase III Clinical Trials 
Phase III clinical trials are larger versions of the Phase II clinical trials. They test for 
extended safety and efficacy of the drug in treating the intended disease. The Phase III clinical 
trials are the most expensive. They typically involve from 1,000 to 5,000 volunteer patients 
(PhRMA, 2010). Usually, the Phase III clinical trials are international. Once the Phase III clinical 
trial is complete, the NDA application and the FDA Review and Approval process begins. This 
phase takes up to three years.  
2.5.4.3 The Ongoing Studies Stage: Phase IV 
The NDA approval by the FDA means that the drug can enter the market. Once the drug 
is on the market, the collection of effectiveness data for the drug continues. Phase IV is focused 
on evaluating the overall safety and efficacy of the drug on a global scale with a wide range of 
people. This global testing is difficult to achieve even with the well-designed Phase III trials. In 
addition, some trials are only conducted in the US.  
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2.5.4.4 Meetings With the FDA 
Throughout the DDP, firms are encouraged to have regular meetings with the FDA. The 
purpose of these meetings is to review the process and design of clinical trials. This ensures that 
FDA requirements are met. In addition, the DDP has a high-failure rate. There are many 
instances of drugs failing in the Phase III trials. For this reason, an interactive approach with the 
FDA can be very beneficial to the firm for a couple of reasons. First, it can result in an early stop 
of drug development to save the unnecessary costs to the firm if the drug is unlikely to be 
approved. Second, it can add to a successful approval and market entry of the drug. The meeting 
with the FDA might be particularly important when a new class of therapeutics is being 
developed. This is the case with the RNAi Therapeutics sector in which Firm Y operates.  
2.5.4.5 The Current Situation With the Drug Development Process (DDP) 
We are in an era of technological advancements in which we expect processes to become 
faster and more profitable for the firm. In addition, we expect a better quality of products, 
especially if these products are related to human health. However, the opposite seems to be true 
for the DDP that is becoming more complicated and costly resulting in more pressure on the 
industry. In 1979, for example, the cost of developing a new drug was estimated US $100 
million, in 2000, it was US $800 million, and, in 2005, it was US $1.3 billion (PhRMA, 2010). 
These estimates also include the cost of developing products that failed to reach the market.  
The main drivers of the cost and complexity of trials seem to be advancements in science 
and technology. Even though these advancements are useful, they generate deeper 
understandings of the safety and efficacy of drugs (PhRMA, 2010). In addition, the development 
of biologics is more complex than small molecule drugs that previously dominated 
pharmaceutical markets. As such, larger and more complicated clinical trials are needed for the 
drug to move to the next stage (PhRMA, 2010). 
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In terms of R&D expenditures, the PhRMA 2010 document reports the distribution by 
each phase of drug development. This data is based on the 2008 statistics and is generated from 
the twenty-nine member firms of the PhRMA. According to the report, the highest spending 
occurs in two of the stages: 27% of spending is allocated to the Pre-human/Preclinical stage and 
32.5% for Phase III clinical trials (PhRMA, 2010). The rest of the R&D cost is distributed as 
follows: 8.2% for Phase I, 12.9% for Phase II, 4.7% for the approval stage, and 14.4% for Phase 
IV (PhRMA, 2010).  
The two most expensive stages are justifiable for the following reasons. The Pre-
human/Preclinical phase is very important. A firm is screening a potential drug in which it will 
continue to invest. The potential drug has to be extensively tested in animals before it is approved 
for humans. The Phase III clinical trials are expected to be the most expensive because they are 
the largest. They also take the longest time to be completed.  
2.5.5 Summary: From the DDP to a 
ew Class of Therapeutics 
The DDP process is complex and costly. There are many regulations and stages in the 
process. The success rate of drugs moving from the discovery stage to the market is still low. The 
process is getting more complex and costly with the evolving scientific and technological 
advances. This is due to both the process and the newly emerging therapeutic opportunities. 
Previously, most of the drugs were chemical in nature. These drugs are termed small molecule 
drugs. However, the establishment and evolution of the biotechnology sector led to new 
therapeutic opportunities. These biotechnology products might be more difficult to take through 
the regulatory process for two reasons. First, the regulatory processes might not be in place yet. 
Second, they might be more complex to validate due to the manufacturing process, and clinical 
safety and efficacy. However, these products potentially have better therapeutic effects in treating 
disease. One example of a newly emerging class of potential therapeutics is the sector termed 
RNAi Therapeutics.  
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2.6 R
Ai Therapeutics: A Potential 
ew Class of 
Therapeutics 
 
2.6.1 An Introduction to R
Ai Therapeutics 
In the next sections, I describe the specific sector in which Firm Y operates. First, I 
discuss different classes of human therapeutics. This leads me to a definition of the sector in 
which Firm Y specializes. Second, I analyze the competitive landscape of this newly emerging 
sector, RNAi Therapeutics.  
2.6.2 Different Classes of Human Therapeutics 
New scientific and technological advancements not only give rise to new markets, but 
also to a new terminology. In addition, until these are well established, defining industries 
involving new entities can be challenging (Trusheim et al., 2010). This leads to a lack of 
harmonization and consistency on the use of terminology related to the biotechnology, 
pharmaceutical and biopharmaceutical industries (Rader, 2005a). Biopharmaceuticals is defined 
as biotechnology-derived pharmaceuticals (Rader, 2005a). Firm Y is a biopharmaceutical firm. 
Broadly, human therapeutics can be divided into drugs and biopharmaceuticals. There is a basic 
difference between the two. Drugs are manufactured chemically involving small molecules and 
other needed chemical substances, and, hence, are considered non-biological (Rader, 2005a). On 
the other hand, biopharmaceuticals are manufactured with biotechnology techniques and involve 
complex biological molecules, and, thereby are considered biological (Rader, 2005a). In addition, 
biologics often cannot be taken orally and must be injected or infused by healthcare providers 
(Trusheim et al., 2010). Overall, they differ in pricing, general adoption, regulations, and how 
they are made available to patients (Trusheim et al, 2010). For the purpose of this analysis, I 
divide biopharmaceuticals into two major groups: biologics and RNAi therapeutics. Next, I 
discuss and define the RNAi Therapeutics sector.  
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2.6.3 A Definition of the Industry Sector in Which Firm Y Specializes 
RNAi therapeutics collectively refers to all the nucleic acid-based therapeutics, and 
includes DNA and RNA-based therapeutics. A type of nucleic acids used in the field of RNAi 
therapeutics is termed oligonucleotides, which are shorter nucleic acids approximately twenty 
nucleotides in length. For this analysis, RNAi therapeutics includes small interfering RNA 
(siRNA), microRNA (miRNA) and antisense oligonucleotide-based therapeutics. Different firms 
develop different types of the oligonucleotide-based therapeutics. I will consider all of these to be 
part of the RNAi Therapeutics sector.  
2.6.4 An Overview of the R
Ai Therapeutics Sector 
In this section, I analyze competitive landscape. RNAi therapeutics brings a new hope 
and approach to treating many human diseases. The RNAi sector is about ten years old 
(Haussecker, 2008). The RNAi mechanism was discovered in a small nematode Caenorhabditis 
elegans (Fire et al., 1998). The RNAi is a mechanism for “silencing” a gene of interest that 
causes a disease. Unlike gene therapy, RNAi therapeutics does not try to “repair” the defective or 
mutated gene on a DNA level; it “silences” the target gene by preventing the protein production 
of that gene (Fire et al., 1998; Bumcrot et al., 2006). Hence, in a very simplified way, if there is 
no production of a defective protein, there will be no disease. The oligonucleotide used to silence 
a gene of interest needs to be delivered to cells of a target tissue or organ. This delivery can be 
carried out by technology platforms such as Firm Y’s PLATFORM X. The RNAi Therapeutics 
sector is still embryonic and the vision of commercialized and widely used RNAi therapeutics 
has not yet been realized.  
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2.6.5 An Analysis of the Potential of R
Ai Therapeutics 
2.6.5.1 Distinguishing Factors of R
Ai Therapeutics 
Since its discovery, the RNAi mechanism has been used as a tool in many genomic 
screens (Haussecker, 2008; Reidhaar-Olson & Vornlocher, 2008). The RNAi mechanism has 
helped identify potential therapeutic targets, which are genes believed to be involved in different 
diseases. Now, RNAi has a potential to become a new class of therapeutics (Haussecker, 2008; 
Bumcrot et al., 2006). RNAi therapeutics can be developed to target those same genes to cure 
diseases. There are several key benefits of RNAi therapeutics compared to traditional small 
molecule drugs and biologics.  
First, RNAi therapeutics starts at the root of a disease, the gene. Therefore, it silences the 
production of a protein at the RNA level and not the protein level, as is the case with many 
current therapeutics. As such, RNAi therapeutics has the potential to treat diseases with a higher 
efficacy. 
Second, the RNAi mechanism is very specific and effective. If an RNAi therapeutic is 
delivered to the target site, it can be highly selective and potent. The high selectivity translates 
into higher safety, and high potency translates into higher efficacy in the clinical trials. Overall, a 
disease can be treated with higher effectiveness.  
Third, RNAi therapeutics has the opportunity to broaden the scope of possible disease 
targets to include those thought to be “undruggable” by other conventional methods (Haussecker, 
2008; Melnikova, 2007; Bumcrot et al., 2006; Rossi, 2007).  
Fourth, RNAi therapeutics falls in between small molecules and biologics. They can 
combine the best of both of these classes. They can be chemically manipulated and easy to 
synthesize. In addition, they are affordable to manufacture, and target identification and 
optimization is fast compared to other conventional methods (Bumcrot et al., 2006). For RNAi 
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therapeutics, the target identification and optimization process is estimated to take weeks rather 
than years (De Fougerolles et al., 2007). This step alone can significantly reduce costs and time 
for the drug development. As I mentioned previously, 27% of the DDP cost is spent on the Pre-
human / Preclinical research stage of the DDP.  
Overall, RNAi therapeutics has a great potential to fill the current gap in human 
therapeutics. It has a potential to treat the disease at the gene level, not the protein level like 
current conventional therapeutics. In addition, this emerging sector is quickly gaining some 
needed regulatory experience. The FDA has already reviewed about fifty different protocols and 
INDs. In addition, more than 10,000 patients in clinical trials have experienced treatment with 
oligonucleotides (Schaffer, 2010).  
2.6.5.2 The Potential Risks of R
Ai Therapeutics 
There are risks and limitations with RNAi therapeutics. First, many genetic diseases 
cannot be treated by RNAi therapeutics. One example is when a mutation in a gene causes a loss 
of function of that gene. As a result, there is no protein made. In these cases, there is no gene 
product to silence or treat. For these types of diseases, RNAi therapeutics cannot be developed. 
Second, the RNAi mechanism is a naturally occurring biological process in the host. As 
such, there are potential safety risks to the host. RNAi therapeutics competes with the host’s 
biological process, or RNAi machinery, to use it to silence the target gene. This approach to 
utilizing host’s natural biological process makes it analogous to viral infections. It can potentially 
overwhelm the host’s natural biological processes resulting in safety implications and side effects 
to the host (Rossi, 2007). 
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2.6.5.2.1 The Limiting Step: The Importance of Delivery in R
Ai Therapeutics 
The most important aspect of RNAi therapeutics is delivery. There was an attempt to 
develop RNAi therapeutics without a delivery system. However, the fact that oligonucleotides 
are not stable in blood serum prompted the need for effective delivery technologies. In fact, 
specific (safe) and potent (efficacious) delivery technologies to the target organs, tissues and 
eventually cells are considered the most limiting step for RNAi therapeutics (Reidhaar-Olson & 
Vornlocher, 2008; Melnikova, 2007, Bumcrot et at., 2006; Haussecker, 2008).   
2.6.5.2.2 Potential Applications of R
Ai Therapeutics 
 There are two different routes of administration of RNAi therapeutics. Direct RNAi 
delivery refers to a local administration of RNAi therapeutics. Systemic RNAi delivery refers to 
intravenous delivery of RNAi therapeutics. Firm Y’s PLATFORM X is a systemic RNAi 
delivery technology. Considering that the RNAi field is embryonic, the advancements in the field 
have been quite rapid. Proof-of-concept for RNAi therapeutics has been shown for several organs 
and indications. Table 1 integrates most of this evidence. It includes the type of administration, 
organs and indications.  
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Table 1: Evidence for RNAi therapeutics Proof-of-Concept 
Source: Adapted from information in Bumcrot et al. (2006). 
In addition, RNAi therapeutics, similar to biologics, can potentially treat more than one 
condition. Currently, there are only two RNAi therapeutics on the market. The first is fomivirsen 
(Vitravene), which is an antisense oligonucleotide-based RNAi therapeutic. It was developed to 
treat cytomegalovirus retinitis (a condition related to eye) in patients with AIDS (Melnikova, 
2007). The second is pegaptanib, also known as Macugen developed by OSI Pharmaceuticals and 
Pfizer for wet age-related macular degeneration (AMD) (Melnikova, 2007). However, both drugs 
have not performed as well as expected. RNAi therapeutics from other nucleic acid classes, for 
example siRNAs, are still waiting to reach the market. However, the two therapeutics on the 
market demonstrate the great potential of this sector. In addition, there are many more in the 
research and clinical development stages.  
2.6.6 Competitive Landscape of the R
Ai Therapeutics Sector 
In this section, I look at the major firms within the RNAi Therapeutics sector. I analyze 
Firm A, Firm B, Firm C, Firm D, and Firm E. These five firms, along with Firm Y, are probably 
the most advanced players within this young sector. These firms develop siRNA, miRNA or 
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antisense oligonucleotide-based RNAi therapeutics. There are new emerging firms with delivery 
platform, RNAi therapeutics or both that have not been considered or included in this analysis. 
Firm A and Firm C are the two leading firms within the RNAi Therapeutics sector. Firm 
A has strong IP, a robust product pipeline and the aspiration of becoming the first fully integrated 
RNAi therapeutics firm. Firm C has probably the second strongest position within this sector, 
with a robust product pipeline.  
All these firms have the hybrid business model. These firms have either delivery or target 
discovery technology as their platform. In addition, these firms develop diagnostic tests and/or 
RNAi therapeutics as their products. They all follow a trend very specific to the RNAi 
Therapeutics sector, with a stream of both public-private and private-private partnerships. A 
number of Big Pharma firms have either partnerships or in-house development related to RNAi 
therapeutics. An example is the Merck-Sirna acquisition. Big Pharma`s strong presence this early 
on in the process indicates its strong interest and belief in this sector. 
2.6.6.1 Firm A 
2.6.6.1.1 Overview 
Firm A’s corporate strategy is to lead the RNAi Therapeutics sector. The firm’s goal is to 
become a fully integrated biopharmaceutical firm (Firm A, 2008). Firm A has a leading position 
in the IP related to RNAi therapeutics. 
2.6.6.1.2 Delivery Focus 
Firm A understands the importance of a delivery system in the RNAi Therapeutics 
sector. Hence, the firm focuses on developing delivery technology for siRNA-based RNAi 
therapeutics. Their current success includes gene silencing of more than twenty-five disease 
targets, in more than five tissues, and in six species, including humans (Firm A, 2008).  
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2.6.6.1.3 Product Pipeline Focus 
Firm A has a diverse and robust product pipeline. It has twenty-two products in its 
pipeline: two in Phase II, four in Phase I, six in the preclinical development stage and ten in the 
discovery/research stage (Firm A, 2008). Firm A’s pipeline consists of its own products and 
those developed through collaborative, partnered, co-developed and joint venture partnerships. 
2.6.6.2 Firm B 
2.6.6.2.1 Overview 
Firm B is a public biotechnology firm. The firm has a hybrid business model with a 
technology platform and an RNAi therapeutics pipeline. The focus of the firm is to develop 
treatments for autoimmune diseases, cancer, infectious diseases, and neurological disorders (Firm 
B, 2007). However, their products are in the early stage of R&D. Firm B has many partnership 
and is involved in various market segments from the RNAi research agents to target validation, 
drug development and disease modelling (Firm B, 2007). 
2.6.6.2.2 Delivery Focus 
Firm B is using its patented technology DNA directed RNA interference for the 
development of its products. DNA is delivered to a cell, which then triggers production of 
corresponding siRNA that triggers the RNAi mechanism. Hence, it starts with the DNA rather 
than RNA, as is case with siRNAs. 
2.6.6.2.3 Product Pipeline Focus 
Firm B is focusing on HIV/AIDS, Hepatitis B and lung cancer where all the projects are 
in collaboration with various partners (Firm B, 2007). The firm is developing two products for 
HIV. The first HIV/AIDS RNAi therapeutics is in clinical trials. The second product is expected 
to enter clinical trials soon. 
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2.6.6.3 Firm C 
2.6.6.3.1 Overview 
Firm C specializes in antisense oligonucleotide-based therapeutics. The firm has a hybrid 
business model with a proprietary drug discovery platform and a product pipeline. The firm 
specializes in discovering a range of potential therapeutics, more than they can develop 
themselves (Firm C, 2010). They hold a strong IP portfolio with more than fifteen hundred 
patents worldwide (Firm C, 2010). The firm out-licenses its products to partners in later 
development stages. These partners complete the drug development process and 
commercialization stage. In addition, the firm generates revenues through its platform. Firm C 
also has a number of partnerships. 
2.6.6.3.2 Discovery Focus 
Firm C has an antisense drug discovery platform. It focuses on many organs and tissues, 
including spleen, liver, kidney, bone marrow and fat cells (Firm C, 2010). 
2.6.6.3.3 Product Pipeline Focus 
Firm C has a robust product pipeline targeting a number of indications. The firm 
specializes in the early drug discovery and development. Firm C focuses on five major indication 
groups: cardiovascular (five products), metabolic (four products), neurodegenerative diseases 
(two products), inflammation (three products) and cancer (four products) (Firm C, 2010). The 
firm also has six other products unrelated to these major indications (Firm C, 2010).  
The cardiovascular group has one product in Phase III, two products in Phase I, and two 
products in the preclinical stage. The metabolic group has one product in Phase II, one product in 
Phase I and two products in the preclinical stage. The cancer group has one product in Phase III, 
one product in Phase II and two products in the preclinical stage. The neurodegenerative group 
has one product in Phase I and one product in the preclinical stage. The inflammation group has 
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three products in Phase II. The group termed others has one product approved, one in Phase II, 
two in Phase I, and one in the preclinical stage. 
2.6.6.4 Firm D 
Firm D is a firm focused on the miRNAs oligonucleotide-based RNAi therapeutics.  
Firm D also has a hybrid business model: it has a proprietary discovery platform and a product 
pipeline. Their proprietary discovery platform combines informatics and high-throughput 
biological approaches to identify miRNAs (Firm D, 2008). Firm D specializes in two lines of 
products: diagnostic tests and the miRNA-based RNAi therapeutics. Firm D currently focuses on 
using miRNAs as biomarkers to develop diagnostic tests for cancer and for women’s health 
indications. In 2009, Firm D commercialized three diagnostic tests (Firm D, 2008).  Currently, 
the firm has three more products in the pipeline. In addition, Firm D is focusing on miRNA-
based therapeutics for liver cancer. The firm has a number of partnerships. 
2.6.6.5 Firm E 
2.6.6.5.1 Overview 
Firm E has a hybrid business mode. The firm has a discovery platform, a delivery 
platform, an RNAi therapeutics product pipeline and a number of partnerships. In addition, the 
firm holds a strong IP portfolio with two hundred issued and worldwide patent applications (Firm 
E, 2010). 
2.6.6.5.2 Delivery Focus 
Firm E has two types of delivery platforms: (1) lipid and (2) polymer-based delivery 
platforms. The lipid delivery platform systemically delivers therapeutics to the liver, 
endothelium, and other tissues (Firm E, 2010). The polymer delivery platform can systemically 
reach any disease target (Firm E, 2010).  
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2.6.6.5.3 Product Pipeline Focus 
Firm E has six different products in their pipeline. The firm is developing four internal 
products and three with partners. One product developed internally is in the clinical stage and 
three are in the preclinical stage. All three products developed with partners are in the clinical 
stage.  
2.6.7 R
Ai Therapeutics Sector Competitive Analysis 
In this section, I use the “Five Forces Model” (Porter, 2008) to analyze the competitive 
landscape of the emerging RNAi Therapeutics sector. Because this sector is embryonic, the 
analysis is based on the limited information available. The analysis considers the six major 
players in the sector. However, there are a number of emerging firms not included in this 
analysis. In addition, the role of partnerships and Big Pharma is considered as well. Figure 3 
depicts a summary of the analysis. Next, I briefly address each of the five forces. 
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Figure 3: The Competitive Analysis of the RNAi Therapeutics Sector 
 
 
Source: Adapted from Porter (2008). 
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(MODERATE) 
THREAT OF 
E
TRY 
(MODERATE) 
SUPPLIER’S 
POWER 
(MODERATE) 
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However, RNAi therapeutics is a novel class of therapeutics that has the potential to treat 
the targeted indications with superiority over other available treatments. If this is the case, the 
bargaining power shifts to the firm. The firm will be able to charge premium price for superior 
RNAi therapeutics. The bargaining power of the firm increases if RNAi therapeutics also 
addresses the unmet medical needs. Overall, buyer power is moderate.  
2.6.7.2 The Threat of Substitutes is Moderate 
The threat of substitutes is moderate overall. This is based on couple of factors. A first 
factor is the number of other human therapeutics available. This factor makes the threat of 
substitutes high. This is due to many small molecules and biologics already available on the 
market and in development. In addition, many of these products are available over the counter. 
Hence, a prescription is not needed for these treatments. In addition, many of these treatments are 
orally available. As such, an oral formulation of the RNAi therapeutics will be beneficial in the 
future. It could increase the value and application of RNAi therapeutics. Furthermore, the 
presence of generics and bio-generics further increases the threat of substitutes.  
The second factor is based on the potential of RNAi therapeutics. Novelty of RNAi 
therapeutics makes the threat of substitutes low. This factor applies if firms focus on a target 
considered “undruggable” by other conventional means. In addition, firms need to develop RNAi 
therapeutics that treats high-unmet medical need with high effectiveness. In such instances, the 
threat of substitutes to this RNAi therapeutics is low. This is due to superior performance of these 
therapeutics where there is no other or a limited number of substitutes available for them. 
Overall, the threat of substitutes is moderate.   
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2.6.7.3 Supplier Power is Moderate 
The bargaining power of suppliers is currently moderate. However, as the sector matures, 
I expect the bargaining power of supplier to increase, especially as more RNAi therapeutics reach 
the market. Firms that have capabilities and the IP to manufacture RNAi therapeutics will have a 
high bargaining power. This is mainly due to delivery aspect of this sector. In a sense, the 
delivery platform is the complementary asset of RNAi therapeutics. The IP and significance of 
product-platforms will shift the power to firms that have capabilities in both. Hence, since one 
cannot go without the other, the manufacturing process of producing both is important. Overall, 
supplier power is moderate. 
2.6.7.4 The Threat of Entry is Moderate 
Currently, the barrier to entry is moderate. Even though there are only few firms in this 
sector, including Firm A, Firm C, and Firm E, they hold a significant barrier in this sector due to 
their IP power. As this industry sector matures, barriers to entry will increase. If new firms 
choose to enter, they will have to go through firms holding the IP in order to develop RNAi 
therapeutics. However, knowledge about other potential oligonucleotides might lead to new 
opportunities. The current IP barriers might not apply to these new opportunities. As such, it is 
possible that more start-up firms will emerge with these new opportunities. The latest example is 
efforts with the miRNA olignonucleotide-based RNAi therapeutics. The delivery aspect of RNAi 
Therapeutics sector further raises the entry barrier. Overall, the threat of entry is moderate.  
2.6.7.5 The Competition is Low 
The competition is low for now. I am basing this analysis only on firms in the RNAi 
Therapeutics sector. As such, there are only few firms currently operating in this sector. In 
addition, there are not many RNAi therapeutics in the market and in development. However, 
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there is emerging competition. As the sector matures, competition is to intensify. Future advances 
in RNAi therapeutics will intensity rivalry. Overall, the rivalry is low.  
2.6.8 The R
Ai Therapeutics Sector Shows Great Promise 
The RNAi Therapeutics sector is embryonic; however, it is rapidly growing. There are 
some key success factors important for this sector. RNAi therapeutics has the potential to be very 
specific, hence safe, potent, and efficacious in treating a disease. As such, it can bring great 
benefits to patients.  
In addition, RNAi therapeutics needs an effective delivery platform. This platform will 
bring RNAi therapeutics to its target site. The more specific delivery is to the intended target, the 
better the overall effectiveness (safety and efficacy) of the treatment. As such, synergy between 
delivery (where to) and RNAi therapeutics (for what) is very important.  
Public and private partnerships are important in the RNAi Therapeutics sector. Many Big 
Pharma firms such as Pfizer, Novartis, Roche, Merck, and Astra Zeneca are investing in this 
sector. In addition, during the global financial crisis, some of the most strategic financial deals 
signed were around the RNAi Therapeutics sector (Melnikova, 2007). This indicates Big 
Pharma’s belief in the future of the sector. Furthermore, FDA experience will increase as more 
RNAi therapeutics enters clinical trials. This will move the sector forward.  
2.7 Summary: From the External Environment to Firm Y 
The previous sections provide the analysis of the external environment in which Firm Y 
operates. Overall, the RNAi Therapeutics sector is rapidly evolving and showing great promise 
for the future of human therapeutics. Firm Y is endeavouring to lead in this sector. In the next 
chapter, I move from the external environment analysis to the internal analysis of Firm Y where I 
assess its organizational capabilities.  
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Chapter 3: A
 I
TER
AL A
ALYSIS OF FIRM Y 
3.1 An Introduction to Firm Y 
Firm Y is a publicly traded biopharmaceutical firm focusing on the development of novel 
RNAi therapeutics. These therapeutics are delivered to the target site via PLATFORM X, Firm 
Y’s leading delivery platform. Firm Y supports its product development pipeline with revenues 
earned from its partnerships. It does so by: (1) out-licensing its technology to its partners and (2) 
by manufacturing products that use PLATFORM X technology for its partners.  
3.2 Firm Y’s Organizational Capabilities  
In the next sections, I examine Firm Y’s organizational resources and capabilities (Grant, 
2008). For resources, I look at tangible and intangible resources. Then I discuss the capabilities 
of Firm Y that give the firm its competitive advantage in the RNAi Therapeutics sector.  
3.2.1 Firm Y’s Resources 
Currently, Firm Y has a leading delivery platform with solid IP and a product 
development pipeline that is expected to grow. The current corporate strategy has two goals:  (1) 
the development of the firm’s product pipeline and (2) nurturing of the firm`s partnerships (Firm 
Y, 2009).  
3.2.1.1 Firm Y’s Tangible Resources 
Despite the recent economic recession, Firm Y has continued to grow. Firm Y’s business 
model is a hybrid one. In terms of the supply chain, it has PLATFORM X delivery technology, 
manufacturing capabilities, and its own products in the development pipeline. Firm Y has a 
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worldwide licence to a number of gene targets via its agreements with one of the RNAi 
therapeutics sector’s leaders (Firm Y, 2009). With these licences Firm Y can discover, develop, 
and commercialize several other potential RNAi therapeutics.  
Firm Y has considerable infrastructure. It has R&D and manufacturing capabilities in-
house. Firm Y is wisely using its internal capabilities by generating revenues via manufacturing 
agreements and out-licensing its delivery PLATFORM X technology. This revenue allows Firm 
Y to grow by developing its own line of products. Firm Y focuses on developing its products and 
evidence of this is Firm Y’s increase in the R&D expenditure throughout the three years. In 2007, 
Firm Y spent less than ten million US dollars on the R&D, almost doubling in 2008 and in 2009 
(Firm Y, 2009). In addition, Firm Y is incrementally improving its PLATFORM X technology 
with the aim to develop a more potent second generation PLATFORM X with a potential broader 
use.  
In 2007, 2008 and 2009 Firm Y’s revenue was in the ten to fifteen million US dollars 
range (Firm Y, 2009). Overall, shareholder’s equity more than doubled from 2007 (Firm Y, 
2009). Next, I look at Firm Y’s intangible resources.  
3.2.1.2 Firm Y’s Intangible Resources 
Intangible resources are very important in the biotechnology industry. Firm’s value in the 
biotechnology sector is heavily based on its IP. Firm Y has solid IP. Its intangible resources 
include PLATFORM X, the current product pipeline, and a stream of strategic partnerships. 
Next, I address each of these in some detail.  
3.2.1.2.1 Firm Y’s Delivery Platform: the PLATFORM X 
Delivery platforms are key to a successful development and a broad application of RNAi 
therapeutics. As such, superior delivery platform in the RNAi Therapeutics sector can bring a 
significant competitive advantage to the firm.  
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Importantly, Firm Y’s organizational capabilities are built around its delivery platform. 
The firm generates revenues and future growth through PLATFORM X. PLATFORM X is a 
systemic delivery platform widely recognized within the RNAi Therapeutics sector. It delivers 
RNAi therapeutics to the target site via intravenous administration. PLATFORM X`s current 
expertise is delivery to one or more organs (Firm Y, 2009).  
3.2.1.2.2 Firm Y’s Product Pipeline 
Firm Y’s product candidates are the siRNA class of RNAi therapeutics. In addition to its 
own products, Firm Y is involved in a number of other product development projects via its 
partners. One product is involved in hypercholesterolemia, a condition also known as high or 
“bad” cholesterol, and it is Firm Y’s leading product candidate. This product is expected to enter 
Phase I/II clinical trials by the end of 2010 (Firm Y, 2009). The second product is the firm’s 
oncology candidate that is expected to enter Phase I clinical trial by the end of 2010 (Firm Y, 
2009).  
3.2.1.2.3 Firm Y’s Stream of Partnerships 
Firm Y follows the RNAi Therapeutics sector trend. It has a number of important 
partnerships that have allowed it to build its organizational capabilities. In 2009, Firm Y earned 
close to fifteen million US dollars through these partnerships (Firm Y, 2009).  
Firm Y has both types of partnerships: public-private and private-private partnerships. It 
has a number of important and diversified licence and collaborative research partnerships. Some 
of these are with Big Pharma, smaller biotechnology firms, and with government and research 
institutions. 
3.2.1.3 Firm Y’s Human Resources 
Firm Y has less than hundred employees and its management team consists of less than 
five executives (Firm Y, 2009). Currently, Firm Y is recruiting in R&D and manufacturing staff 
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(Firm Y, 2010). The expansion of the R&D team is in areas of infectious diseases and oncology. 
The firm’s core capabilities are in R&D, manufacturing, and forming strategic partnerships. 
Next, I address these core capabilities.  
3.2.2 Firm Y’s Capabilities 
Firm Y has three core capabilities that give rise to the firm’s competitive advantage: (1) 
PLATFORM X delivery technology, (2) in-house manufacturing, and (3) strategic stream of 
partnerships. PLATFORM X gives Firm Y the opportunity to build diverse partnerships. These 
partnerships lead to the need to combine PLATFORM X with Firm Y’s manufacturing 
capabilities in order to generate revenues. In addition, these partnerships result in Firm Y’s 
ability to pursue its own product pipeline and ensure further growth and vertical integration of the 
firm. 
3.3 Summary: Firm Y Has Solid Organizational Capabilities 
The internal analysis of Firm Y indicates that the firm has solid organizational 
capabilities. The firm’s strategy and organizational capabilities, along with the industry’s key 
success factors, should lead to a strong competitive advantage of the firm within its industry 
(Grant, 2008). As such, Firm Y`s organizational capabilities and its strategy should provide it 
with a strong competitive advantage within the RNAi Therapeutics sector. In the next section, I 
analyze Firm Y`s current competitive advantage. In addition, I assess Firm Y`s potential to 
further maximize its organizational capabilities to ensure sustainable competitive advantage 
within the RNAi Therapeutics sector.  
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Chapter 4: FIRM Y 
EEDS 
EW PRODUCTS I
 ITS 
PIPELI
E TO SHOWCASE LO
G TERM GROWTH 
POTE
TIAL 
The internal analysis demonstrates that Firm Y has solid organizational capabilities that 
provide Firm Y with a competitive advantage within the RNAi Therapeutics sector. As such, 
Firm Y is one of few firms that lead this sector. However, is Firm Y fully utilizing its 
organizational capabilities? It has a great delivery platform needed for the RNAi Therapeutics 
sector and manufacturing capabilities. In addition, Firm Y follows the sector’s trend in having a 
diverse partnership portfolio.  
Unlike Firm A, Firm C, and Firm E, Firm Y does not have a robust IP portfolio. In 
addition, the firm has only few products in its pipeline despite all the partnerships. This is not 
sufficient for the biotechnology industry, which has a high-failure product development rate. As 
such, the failure of any of Firm Y’s products in clinical trials would significantly devalue the 
firm. Therefore, if a firm in the biotechnology industry has the means to expand its product 
pipeline, it should do so. In addition, the RNAi Therapeutics sector is still in its infancy and 
RNAi therapeutics still needs to be commercially validated. Therefore, the high-risk, high-failure 
rate for the industry is higher for the RNAi Therapeutics sector.  
Hence, Firm Y should minimize its risk by having more products in its pipeline. This 
brings me back to the question: is Firm Y fully utilizing its organizational capabilities? 
Considering the firm’s resources, Firm Y still has the right to a number of targets via its 
worldwide licence agreements. Therefore, Firm Y should identify new market opportunities to 
expand its current product pipeline. However, new market opportunities should be considered 
against Firm Y’s core competencies.  
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In the next sections, I identify new market opportunities for Firm Y based on 
PLATFORM X’s ability to deliver RNAi therapeutics to the liver. Then, I further analyze these 
new market opportunities according to: (1) Firm Y’s external environment, (2) Firm Y’s 
organizational capabilities, and (3) the competitive environment for each indication. I conclude 
this analysis with an evaluation of the identified market opportunities. In addition, I provide 
strategic recommendations to Firm Y.  
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Chapter 5: THE APPROACH TO THE 
IDE
TIFICATIO
 A
D EVALUATIO
 OF 
EW 
MARKET OPPORTU
ITIES FOR FIRM Y 
5.1 An Introduction to the Identification of 
ew Product 
Opportunities for PLATFORM X 
 
The external and internal analysis shows that Firm Y needs to expand its product 
pipeline. As such, the purpose of this chapter is to describe methodology I used to identify and 
assess new market opportunities. These are based on PLATFORM X’s competency to deliver 
oligonucleotides to specific organs. In addition, I include the evaluation criteria used for the 
overall evaluation and recommendations for Firm Y.  
5.2 The Scope: Identification of 
ew Indications for 
PLATFORM X 
 
The overall goal for Firm Y is to identify new target opportunities for the expansion of 
its current product development pipeline to treat one or more new indications. To leverage on 
PLATFORM X’s core competency, I focus on finding indications related to diseases that have 
potential gene targets in the liver that are eligible for treatment with RNAi therapeutics. First, I 
identified new opportunities based on scientific feasibility criteria listed in Table 2. Second, I 
assess the shortlisted group according to business feasibility criteria listed in Table 3. Third, I 
consider each identified opportunity relative to the firm based on the criteria listed in Table 4. I 
conclude with the comprehensive evaluation of each strategic opportunity to make 
recommendations for Firm Y.  
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5.3 The Methodology: From Genes to Potential Indications 
for PLATFORM X 
 
The approach taken to identify a number of potential indications was broad. The Internet 
was used as a primary research tool. The basis for the search was the potential to use the RNAi 
mechanism to treat a disease with focus on liver gene targets. The selection criteria for the 
evaluation of opportunities are based on scientific and business feasibility specific to Firm Y.  
First, the identified opportunities were assessed based on the scientific feasibility criteria 
listed in Table 2.  
Table 2: A List of Scientific Feasibility Criteria 
 
The most important criterion was for the disease to have genetic basis in order to make it 
eligible for RNAi therapeutics. The initial research resulted in the following list of indications: 
(1) diabetes with three related sub-indications (Type 2 diabetes, non-alcoholic fatty liver disease, 
and metabolic syndrome), (2) liver cancer, (3) cardiovascular diseases with three sub-indications 
(dyslipidemia, atherosclerosis and Budd-Chiari syndrome), (4) Alagille syndrome, and (5) 
EVALUATIO
 CRITERIA DESCRIPTIO
 OF EACH CRITERIO
 
ELIGIBLE FOR R
Ai 
 Is the indication eligible for RNAi therapeutics?  
 Is there a gene to be silenced?  
 What is the likeliness that disease will be treated with high 
effectiveness?  
 Will treatment with RNAi therapeutics address the targeted 
indication/target site? 
PROOF-OF-CO
CEPT EVIDE
CE 
 How well are potential targets validated preclinically?  
 What about already available treatments?  
FOCUSED GE
E TARGET  Is the indication complex where it might involve many genes? 
LIVER SPECIFICITY 
 Where is the potential target expressed?  
 Is the target only expressed in the liver?  

OTE 
 These are based on limited data obtained for this analysis.  
 Some of the criteria were developed in collaboration with Firm 
Y’s R&D team. 
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Hepatitis B. After consultation and input from the R&D team at Firm Y, two more indications 
were considered: hemochromatosis and liver fibrosis.  
The list was shortened mainly based on consultation with the R&D team. The remaining 
indications are: (1) Hepatitis B (HBV), (2) liver fibrosis, (3) liver cancer, (4) diabetes, and (5) 
cardiovascular diseases (CVDs). In addition, metabolic syndrome is considered in relation to 
diabetes and CVDs. For the purpose of this analysis, I classified the main indications into two 
groups. These are based on:  (1) interconnectedness of indications related to each other, and (2) 
group’s liver specificity. I refer to these two groups as the liver diseases group and the “liver-
associated” group.  
The liver diseases group consists of HBV, liver fibrosis, and liver cancer (HCC). This 
group is liver specific since the indications are classified as diseases specifically affecting the 
liver. The “liver-associated” group consists of diabetes, cardiovascular diseases (CVDs), and 
related metabolic syndrome. This group is less specific to the liver since these diseases also affect 
other organs. However, these indications have potential gene targets, which can be silenced in the 
liver. As such, these diseases show potential for treatment with RNAi therapeutics delivered to 
the liver. Therefore, for the purpose of this analysis I refer to this group as the “liver-associated” 
group. 
Second, each group was assessed based on its commercial potential according to the 
business feasibility criteria listed in Table 3. In the next chapter, I analyze these shortlisted 
indications as new market opportunities. The evaluation criteria for the commercial potential of 
the indications are based on, and limited to, the data collected for this analysis.   
  
 43 
 
Table 3: A List of Business Feasibility Criteria 
 
EVALUATIO
 CRITERIA DESCRIPTIO
 OF EACH CRITERIO
 
MARKET POTE
TIAL  Based on prevalence, incidence and mortality rate. 
U
MET MEDICAL 
EED 
 Estimated from the data collected; also partially 
incorporates route of administration. 
COMPETITIVE LA
DSCAPE 
 Includes brief overview of products on the market and in 
development, as well as in the RNAi therapeutics sector.  
 Mainly based on the number of products in the clinical 
trials studies. 
FDA EXPERIE
CE WITH R
Ai 
THERAPEUTICS 
 Mainly based on the current evidence of the FDA’s 
experience with RNAi therapeutics. 

OTE 
 These are based on limited data obtained for this analysis.  
 Most of the criteria were suggested by Firm Y’s 
management. 
 
Third, I made a list of evaluation criteria for Firm Y in order to integrate all of the 
information obtained and analysis conducted. These evaluation criteria are listed in Table 4 and 
are mainly based on the external and internal analysis. This adds to the overall evaluation of 
strategic options and recommendations for Firm Y.   
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Table 4: A List of Corporate Criteria Specific for Firm Y 
 
Rationale for these criteria is that Firm Y needs to have necessary organizational 
capabilities in order to excel in developing RNAi therapeutics for newly identified indications. 
This strategy will further maximize the potential for the Firm Y to succeed in developing such 
treatments to create value for itself and its shareholders. For example, some indications might 
have a larger market size like CVDs. However, is pursuing CVDs the best strategic option for 
Firm Y? Would this be in line with its organizational capabilities and corporate strategy? This 
comprehensive strategic approach to evaluating new market opportunities can maximize Firm 
Y’s ability to develop superior treatments for the identified indications providing Firm Y with the 
competitive advantage over other treatments intended for the same indications.  
  
EVALUATIO
 CRITERIA DESCRIPTIO
 OF EACH CRITERIO
 
CORPORATE PIPELI
E 
GROWTH (DIFFERE
TIATIO
) 
 Will new targets bring focused differentiation in line with 
corporate goals and Firm Y’s organizational capabilities? 
 Will overall value and growth potential of Firm Y be higher? 
 Will shareholder’s value be higher? 
SY
ERGY WITH  
PLATFORM X 
 How specific is the medical condition to the liver? 
 More liver specific the better it is to avoid off-target effects. 
This adds synergy with PLATFORM X 
SY
ERGY WITH CURRE
T 
PRODUCTS 
 Will new targets benefit and work synergistically to some 
extent with the current pipeline?  
 Can Firm Y’s current product development capabilities be 
transferred to a new line of potential targets and products? 
PART
ERSHIP SY
ERGY 
(CURRE
T) 
 Will new targets / market opportunities create synergy with 
Firm Y’s current R&D and manufacturing partnerships? 
PART
ERSHIP SY
ERGY 
(FUTURE) 
 Will new market opportunities create future partnership 
opportunities? 
EXIT/I
TEGRATIO
 
(STRATEGY) 
 Will new targets / market opportunities create value for Firm Y 
and its shareholders in terms of potential exit strategy?  
 For acquisition, will Firm Y have higher overall valuation in 
terms of tangible and intangible assets? 
 Or, will Firm Y as a result achieve further forward integration 
in the value chain?  
 Will this add value to Firm Y in terms of Big Pharma and the 
RNAi Therapeutics sector in which it competes and operates? 

OTE  These are based on limited data obtained for this analysis 
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5.4 Summary: From Identification to Analysis of Potential 
Identifications for PLATFORM X 
 
The research led to a number of potential indications for Firm Y’s PLATFORM X 
technology. The initial list was shortened mainly based on input from Firm Y’s R&D team. The 
new list includes two main groups of indications. The next chapter provides information and 
analysis needed to integrate the external, internal and new market opportunities assessment 
suitable for Firm Y according to the three main evaluation categories presented in this chapter. 
This leads to the overall evaluation of strategic options and final recommendations for Firm Y.  
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Chapter 6: A COMMERCIAL POTE
TIAL 
A
ALYSIS OF 
EWLY IDE
TIFIED I
DICATIO
S 
FOR FIRM Y 
6.1 Introduction: Business Feasibility of 
ew Market 
Opportunities 
 
The sections in this chapter present business feasibility data for each indication within 
the two groups. The two groups are: (1) liver diseases, and (2) liver-associated diseases. The liver 
diseases group consists of Hepatitis B (HBV), liver fibrosis, and liver cancer. The liver-
associated group consists of diabetes, CVDs, and related metabolic syndrome. However, due to 
time and resources, data on some of the indications is limited. For example, the competitive 
landscape and unmet medical needs for diabetes and CVDs is difficult to assess.  
The chapter sections include an overview of each indication, its market size, current and 
future standard of care, unmet medical needs, and competitive landscape. The focus is on the 
North American market, in particular the United States. The competitive landscape estimates 
used for this analysis are based on open clinical trial studies from the ClinicalTrials website. The 
number of new products in development might be overestimated due to enrolment in multiple 
clinical trials. 
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6.2 The Liver Diseases Group: HBV/Liver 
Fibrosis/Hepatocellular Carcinoma (HCC) 
 
6.2.1 An Introduction to Liver Diseases 
Liver is the largest and one of the most important organs in the human body. Hepatitis 
viruses and other chemicals cause liver diseases. In addition, there are adult and paediatric liver 
diseases. Treatments are limited and there is a need for new ones.  
There are several stages in the progression of liver disease as shown in Figure 4. The 
progression from a healthy liver to liver failure is quite consistent. Moreover, liver diseases have 
a wide range of symptoms from ones that are undetectable to those that can result in death 
(American Liver Foundation, 2007). 
Figure 4: Liver Disease Progression from Inflammation to Liver Failure 
 
Source: Adapted based on information from the American Liver Foundation website (2007). 
6.2.1.1 There is Time for Regeneration 
A liver disease starts with inflammation of the liver (American Liver Foundation, 2007). 
This is usually caused by two factors: (1) the body is fighting an infection, or (2) the liver is 
healing itself due to its regenerative capabilities. One of the problems in detecting the disease is 
that the liver is an internal organ. As such, a patient may not feel the inflammation, and will not 
be diagnosed and treated. Thus, the inflammation might continue to cause more damage and can 
progress to liver fibrosis (American Liver Foundation, 2007).  
Healthy Liver Inflammation Fibrosis Cirrhosis
Liver 
Cancer
Liver 
Failure
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 Fibrosis refers to scarring of the liver. An untreated inflammation of the liver leads to 
scarring that can keep blood from flowing through the liver (American Liver Foundation, 2007). 
If diagnosed and treated on time, the liver can regenerate to a healthy state, and if not, further 
scarring of the liver can lead to cirrhosis.  
Cirrhosis, if left undiagnosed and untreated, will cause permanent liver scarring. In some 
patients, cirrhosis leads to cancer. At this stage, patients are likely to have symptoms resulting in 
a higher chance that patients will seek medical help. Cirrhosis and HBV are considered leading 
risk factors for primary liver cancer (American Liver Foundation, 2007). 
In liver cancer patients, the main goal is to preserve as much of the remaining healthy liver 
as possible. Undiagnosed and untreated liver cirrhosis or liver cancer leads to liver failure. At this 
stage, most of the liver is not functioning. This is life threatening to a patient where the last 
option for the patient is liver transplantation. 
6.2.1.2 A Summary of Liver Diseases 
 Early diagnosis and treatment is very important to treating liver diseases. There is a high 
chance of liver failure if liver disease progresses to cirrhosis and cancer. At this stage, treatment 
options are very limited and liver transplantation might be the only option. As a result, there is a 
need for novel approaches for diagnosis, treatment, and prevention of liver diseases using 
molecular and genetic advancements to develop new products (Blum, 2007). Thus, there is an 
opportunity for RNAi therapeutics, and more specifically, for Firm Y. 
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6.2.2 Healthcare Costs for Liver Diseases in the US 
The US National Institute of Health (NIH) website lists 1477 open clinical trial studies 
related to liver diseases (ClinicalTrials, 2010). Liver diseases have a significant impact on the US 
healthcare system. In the next section, I address the healthcare costs of liver diseases in the US, 
as well as, the increasing incidence of liver diseases due to the aging population and Baby 
Boomers.  
 Liver disease is the twelfth most common cause of death in the US (Davis & Roberts, 
2010). The prevention and/or monitoring of the hepatitis infections can be important for 
progression and management of liver diseases. This is because Hepatitis B (HBV), Hepatitis C 
(HCV) and fatty liver diseases are more common in Baby Boomers. As a result, liver cancer is 
expected to be more prevalent in the future (Davis & Roberts, 2010). The Baby Boomers group 
in the US refers to 78 million seniors born between 1946 and 1964 (Davis & Roberts, 2010). In 
addition, life expectancy has increased from 68 years to an estimated 80 years of age. As such, 
chronic diseases represent a major trend in the future. It is estimated that 70% of chronic diseases 
are responsible for deaths and 80% of health care costs in the US (Davis & Roberts, 2010). These 
costs are mainly due to emergency visits and hospitalization. Hence, these costs might be reduced 
with effective treatments.  
Overall, the impact of liver diseases on the US healthcare system is considerable. There 
are many risk factors associated with progression of liver diseases that are preventable. One 
example is alcohol intake. It is estimated that 45% liver disease mortality in the US is linked to 
alcohol consumption (Davis & Roberts, 2010). However, there are other high-risk factors more 
difficult to manage such as hepatitis infections, in particular Hepatitis B (HBV) and Hepatitis C 
(HCV). These might be good therapeutic targets important for both the acute and chronic 
prevention and overall progression of liver diseases.  
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HBV and HCV have significant health and cost implications. Their effective prevention 
and monitoring can improve human health and reduce healthcare costs. This is important for the 
aging population with a longer life span. The aging population will become a global challenge 
and significant burden to already saturated healthcare systems around the world. Emphasis on 
early diagnosis and prevention is important. For further analysis, I look at the liver diseases 
group. This group includes HBV, liver fibrosis, and liver cancer (HCC). I start with HBV, 
continue with liver fibrosis and conclude with liver cancer. 
6.2.3 Hepatitis B (HBV) 
Hepatitis refers to inflammation of the liver mainly caused by viruses. There are A, B, C, 
D and E classes of hepatitis virus. Types A, B and C are the most common in the US (CDC, 
2009). The severity of HBV infection depends on whether the infection is acute or chronic. If 
acute, symptoms are mild and last several weeks while chronic symptoms can progress to liver 
failure (CDC, 2010).  
6.2.3.1 Market Size 
In the US, there are between 800,000 and 1.4 million people with chronic HBV infection, 
and globally there are an estimated 350 million people with chronic HBV (CDC, 2009). In the 
US, the prevalence in the general population is considered to be around 1%. In populations, such 
as native Alaskans or Asians, the prevalence is estimated to be 5-15% (Carey, 2009). There is 
clear evidence that HBV is a precursor to other liver conditions. In at least 40% of patients, 
infection with HBV will lead to either HCC or liver failure (CDC, 2009). In 2007, 43,000 people 
in the US were newly infected with HBV. The infection rate is the highest among adults between 
ages 25-44 (CDC, 2009). An estimated 620,000 people worldwide die from diseases related to 
infections with HBV (CDC, 2009).  
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6.2.3.2 Current Standard of Care 
Currently, there is a prophylactic vaccine available for HBV. Since its wide adoption 
among both children and adults, the incidence of acute infection in the US has dropped 
dramatically (Blum, 2010). The vaccine has been available since 1982 and it took 18 years to 
implement it in 135 countries (Bosch, 2004). It is 95% effective against infection and its chronic 
consequences (WHO, 2010).  
Chronic HBV remains a global health concern and there are few antiviral therapies 
available. However, developing a guideline for their use is challenging. In the US, the majority of 
patients infected with HBV are not taking these antivirals (Davis & Roberts, 2010). Currently, 
there are two classes of approved therapies. Table 5 depicts a summary of treatments for HBV. 
Table 5: A Summary of Treatments for Chronic HBV Infection 
 
Source: Adapted from information in Hepatology clinical textbook in Chapter 9 (2010). 
 

UCLEOSIDE A
ALOGUES (antivirals) 

ame Frequency of Treatment (oral) Duration 
Lamivudine (Zeffix®) daily long-term 
Telbivudine (Sebivo®) daily long-term 
Entecavir (Baraclude®) daily long-term 

UCLEOTIDE A
ALOGUES (antivirals) 

ame Frequency of Treatment (oral) Duration 
Adefovir dipivoxil (Hepsera®) daily long-term 
Tenofovir disoproxil fumarate 
(Viread®) 
daily long-term 
I
TERFERO
 α 

ame Frequency of Treatment Duration 
Standard interferon α-2a 
(Roferon®) 
3x/week 4-6 months 
Standard interferon α-2b 
(Intron A®) 
3x/week 4-6 months 
Pegylated interferon α-2a 
(Pegasys®) 
1x/week 48 weeks 
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The first class is interferon α-based therapies that can address both viral replication and 
host’s immune response (Bömmel et al., 2010). The second class is antiviral 
nucleoside/nucleotide analogues. This class inhibits HBV DNA replication (Bömmel et al., 
2010). While the number of approved treatments is increasing, the application of these therapies 
remains problematic. For example, interferon α-based therapies are not recommended for long-
term treatments. This is due to tolerability and side effects (Bömmel et al., 2010). Antiviral 
nucleoside/nucleotide analogues are better tolerated and can be prescribed for longer use. 
However, the problem with viral therapies is that viruses mutate at high rates. As such, possible 
resistance of the virus to the therapies might jeopardize the efficacy of these treatments. The best 
approach involves early detection and effective treatment with what is available (Bömmel et al., 
2010). 
6.2.3.3 Competitive Landscape 
The US National Institute of Health (NIH) website lists 298 open clinical trial studies 
related to HBV (ClinicalTrials, 2010). In terms of RNAi therapeutics, Firm B is working on 
HBV. Their product is in the early stage of development. Overall, the competition for HBV is 
low. 
6.2.3.4 Unmet Medical 
eeds and Future Trends 
Incidence of HBV will continue to decline because of standardization of the HBV 
vaccine (Davis & Roberts, 2010). However, there is a need for therapies for HBV even with the 
available vaccine. Chronic infections prevalent in current generations will persist for some time. 
Hence, the next stage is treatment of chronic HBV. The main aim of chronic HBV therapy is to 
reduce the future impact it has on liver disease progression from inflammation to liver failure and 
hepatocellular carcinoma (HCC) (Davis & Roberts, 2010). 
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6.2.4 Liver Fibrosis 
 Liver fibrosis can progress from mild liver inflammation to liver failure if not treated. 
Many underlying conditions such as hepatitis infection, alcohol abuse, dietary component and 
others can contribute to liver fibrosis. Some studies show that liver fibrosis can be the cause of 
non-alcoholic steatohepatitis (NASH) (Bataller & Brenner, 2005). NASH is a component of 
metabolic syndrome that is characterized by obesity, Type 2 diabetes mellitus, and dyslipidemia 
(Bataller & Brenner, 2005). This further proves that liver fibrosis is a disease of many underlying 
conditions. As such, I mention it briefly in context of the liver disease group. Hence, RNAi 
therapeutics for liver fibrosis would benefit treatments for the liver. 
6.2.4.1 Market Size 
Prevalence and incidence statistics for liver fibrosis are difficult to find because it is not a 
well defined indication. A recent study using FibroTest predicts the prevalence of advanced 
fibrosis to be 2.8% in the general population that is forty years of age or older (Poynard et al., 
2010). 
6.2.4.2 Current Standard of Care 
There is no standard treatment for liver fibrosis. If it leads to liver failure, patients 
undergo liver transplantation. In many patients with HCV, infection will recur and repeated liver 
transplantation is required (Bataller & Brenner, 2005). Diagnosis, treatment, and monitoring 
progress of the disease are difficult. Biopsy is the standard of care for diagnosis of liver fibrosis. 
Hence, there is a real need for non-invasive methods. Many non-invasive biomarker tests are in 
development with the FibroTest and Fibroscan being the most validated (Bataller & Brenner, 
2005). Future diagnostic advancements will lead to better and earlier diagnosis. The goal is to 
eliminate the need for biopsy. Overall, there is potential for RNAi therapeutics to be used as an 
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antifibrotic therapy. The ideal therapeutic needs to be liver-specific, safe, well tolerated, and 
efficacious (Bataller & Brenner, 2005).  
6.2.4.3 Competitive Landscape 
The US National Institute of Health (NIH) website lists 195 open clinical trial studies 
related to liver fibrosis (ClinicalTrials, 2010). Due to the nature of liver fibrosis, most trials 
include other indications, for example, HCV, heart failure, obesity, metabolic syndrome, and 
insulin resistance. In terms of RNAi therapeutics, Firm C is developing a drug for fibrosis that is 
in Phase II. Overall, the competition for liver fibrosis is low. 
6.2.5 Liver Cancer and Hepatocellular Carcinoma (HCC) 
Primary liver cancer refers to cancer that starts in hepatocytes. There are four different 
types of liver cancer: Hepatocellular Carcinoma (HCC), Cholangiocarcinoma, Hepatoblastoma 
and Angiosarcoma, or hemangiosarcoma (MayoClinic, 2010). HCC is the most common type of 
liver cancer and the focus of this analysis. HCC affects both children and adults. HCC is different 
from other cancers in that 80% of patients have two diseases: cirrhosis and cancer (Carr, 2004). 
In addition, there is a gender preference in the estimated 80% of patients who also suffer from 
cirrhosis. Those patients show a range of three to one, and up to nine to one, male predominance 
of disease compared to women (Carr, 2004). HCC is a whole organ disease in which metastasis is 
rare or absent. This is because patients die from liver failure before the metastasis can happen. 
Overall, HCC is specific and a good target for PLATFORM X.  
6.2.5.1 Market Size 
There are several important facts about HCC. First, it is the third leading cause of cancer 
mortality worldwide (Altekruse et al., 2009). Second, it primarily affects elderly patients with 
liver fibrosis or cirrhosis (Gary & Roberts, 2010). In addition, there is evidence that patients 
infected with HCV and HBV will progress to HCC. The incubation period is long, however. It 
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can take anywhere from two to four decades for a disease to progress from inflammation to HCC 
(Carr, 2004). Third, mathematical models have predicted that prevalence of HCC due to HCV is 
expected to increase to 2020 and possibly beyond (Davis et al., 2003). Further evidence shows a 
link between HBV, HCV and HCC. 75% to 80% of primary liver cancers in patients are 
correlated with chronic infection with HCV (in 25% to 30%) or with HBV (in 50% to 55%) 
(Bosch et al., 2005). Even though HCV and HBV are on decline, HCC is on the increase in the 
US.   
Worldwide prevalence of liver cancer is estimated to be 564,000 (398,000 in men and 
166,000 in women) people per year (Bosch et al., 2004). Overall, liver cancer accounted for 5.6% 
of all tumours: 7.5% in men and 3.5% in women. In high-risk countries, the onset of HCC is 
from age 20 to 50.  
Liver cancer has a very high mortality rate. As such, incidence and mortality are assumed 
to be equal. Both frequency and mortality are on the increase in the US (Hoofnagle, 2004; Bosch, 
2005). This might be due to the aging population and higher life expectancy trend. In addition, 
incidence of HCC is on the rise in North America, Central Europe, Japan, Australia, and the 
United Kingdom (Bosch, 2004). The 15-year study of the HCC profile in the US reported by Carr 
is summarized in Table 6. 
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Table 6: HCC Profile Identified in a 15 Year Long Study in the US 
 
Source: Adapted from information reported by Carr (2004). 
 Risk factors associated with the development of liver cancers are gender, age, chronic 
infection with HCV and HBV, cirrhosis, certain inherited diseases, diabetes, exposure to dietary 
aflatoxins, obesity, and alcoholism (MayoClinic, 2010, Bosch et al., 2004). A recent study also 
assessed that HCC has a significant impact on the US healthcare system where the annual cost of 
HCC was estimated to be US $454.9 million with each patient costing US $32,907 (Lang et al., 
2009). An estimated 82.9% of this cost is due to health care and 10.8% to lost productivity (Lang 
et al., 2009). 
6.2.5.2 Current Standard of Care 
 There are three ways of diagnosing liver cancer: (1) blood tests, (2) imaging tests with 
ultrasound, including CT, MRI, chest X-ray, and bone scan, and (3) biopsy (MayoClinic, 2010). 
Biopsy is the standard of care. However, the liver is already scarred in HCC. As such, biopsy is 
considered even more invasive and risky as it might lead to bleeding, bruising, and infection 
(MayoClinic, 2010). Hence, better non-invasive diagnostic tools are needed. 
Cancer is a complex disease, and HCC is no different. In fact, cirrhosis potentially makes 
HCC worse than other cancers. Current treatments for HCC are very limited. The mortality rate is 
high due to late diagnosis and even if patients are diagnosed, there is a lack of standardized 

UMBER OF PATIE
TS  1700 
HCC CHARACTERISTIC 
 75% had bilobar cancer 
 72% had portal vein thrombosis 
 65% had 3 or more tumor masses 
OTHER CO
DITIO
S 
 30% HCV infection 
 20% infected with HBV 
 28% alcohol-associated cirrhosis 
 20% no identifiable underlying liver disease 
GE
DER PREFERE
CE  2.5:1 male predominance ratio 
AGE  average 56 years; range: 6 months to 92 years 
SUB-GROUP  20% found ineligible for treatment; median survival: 3 months 
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guidelines for monitoring. However, non-invasive biomarker tests should improve diagnosing, 
monitoring, and treatment of HCC. 
Current treatments include surgery and chemotherapy (Carr, 2004). Surgery includes 
either the removal of a part of the liver or liver transplantation. Chemotherapy is very limited and 
more harmful than useful due to cirrhosis. Drugs in current use are doxorubicin (Adriamycin) and 
cisplatin, and a newer promising treatment is liver hepatic artery chemoembolization (TACE) 
that is considered a new benchmark for future treatment (Carr, 2004). The approach is to inject 
chemotherapy drugs directly into the liver so that it is more efficacious and has less negative 
impact on the already fragile liver. New treatments include angiogenesis inhibitors, such as 
Sorafenib (Nexavar), which adopt a more targeted approach (Lang et al., 2008). Sorafenib 
achieves improvement for patients, but only for a few months. The combination of 
surgery/transplantation and chemotherapy/TACE is likely to be most beneficial to patients. This 
is due to targeting both cirrhosis and the tumours of HCC.  
6.2.5.3 Unmet Medical 
eed 
HCC is a very serious disease and current treatment options are highly invasive, costly, 
not beneficial to the patient, and as a result are not meeting the medical needs. Chemotherapy is 
largely ineffective and toxic to the already scarred livers (Hoofnagle, 2004; Carr, 2004), and 
therefore, better therapies for treating cirrhosis are needed. Liver transplantation is invasive, yet it 
is not very beneficial for many patients. Especially in HCV patients, the cancer recurs and as 
such, the liver transplantation might have to be repeated. In addition, an estimated 50% of 
patients with HCC do not pass eligibility criteria for transplantation, and are not treated (Carr, 
2004).  
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6.2.5.4 Competitive Landscape  
The US National Institute of Health (NIH) website lists 574 open clinical trial studies 
related to liver cancer (ClinicalTrials, 2010). In terms of RNAi therapeutics, Firm A has a liver 
cancer drug in Phase I. Firm D is testing several liver cancer targets in collaboration with other 
firms. For HCC, the US National Institute of Health (NIH) website lists 274 open clinical trial 
studies (ClinicalTrials, 2010). Overall, the competition for HCC is low to medium. 
6.2.5.5 Future Standard of Care 
In general, prevention, early detection, and more targeted therapies are needed 
(Hoofnagle, 2004). With 50% of patients remaining untreated there is a high need for non-
invasive or minimally invasive diagnostic tools and therapies. Hence, RNAi therapeutics could 
be an important non-toxic approach to treating HCC based on molecular pathways and genes. In 
addition, non-invasive diagnostic and prognostic biomarker tests are emerging and will be 
significant in the future because they can accelerate early detection and reduce the need for 
invasive biopsy. As such, these diagnostic advancements can lead to faster clinical trials and 
possibly accelerated FDA approvals where patient recruitment and monitoring will be easier. 
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6.3 The Liver-Associated Group: 
Diabetes/Cardiovascular Diseases (Metabolic 
Syndrome) 
 
6.3.1 Metabolic Syndrome in Relation to Diabetes and CVDs 
Metabolic syndrome represents a common combination of conditions and risk factors 
that can lead to diabetes and cardiovascular diseases (CVDs) (MedlinePlus, 2010). The research 
of potential targets for this analysis also identified a correlation between metabolic syndrome, 
diabetes, and CVDs. For the purpose of this analysis, I grouped these three indications. Next, I 
analyze diabetes and CVDs in more detail. Metabolic syndrome is a condition linking the two. 
6.3.2 Diabetes 
Diabetes mellitus, commonly known as diabetes, represents a group of diseases the 
hallmark of which is high glucose levels. This is due to the body’s inability to produce or use a 
hormone called insulin (CDC, 2009). Pancreatic beta cells are the only cells in the body that 
produce insulin to regulate blood glucose levels. While diabetes, if not prevented or treated, can 
lead to death, many lifestyle related risk factors are preventable. There are four different 
categories of diabetes: Type 1, Type 2, gestational, and others.  
Type 1 diabetes is a serious condition in which the patient’s immune system attacks 
pancreatic beta cells where patients cannot produce insulin. Type 1 diabetes accounts for 
approximately 5-10% of all diabetes (CDC, 2009). Type 1 diabetes risk factors are autoimmune, 
genetic, and environmental. Type 2 diabetes accounts for 90-95% of all the diagnosed diabetes 
(CDC, 2009). While patients with Type 2 diabetes produce insulin, their bodies are not utilizing 
it properly, and as such, this can lead to chronic insulin resistance. If chronic diabetes is not 
treated, it can have serious implications for a patient. However, Type 2 diabetes is highly 
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preventable. Patients can prevent or improve their condition by lowering the risk factors related 
to their lifestyle. Some of the risk factors are obesity, physical inactivity, and age. Another type 
of diabetes is gestational diabetes caused by glucose intolerance that occurs during pregnancy 
(CDC, 2009). The fourth category results from genetic conditions and it accounts for an 
estimated 1-5% of diagnosed diabetes (CDC, 2009). For diabetes-associated complications, 
control of blood glucose, pressure and lipids, is important. This correlation and connectedness led 
me to analyze and evaluate diabetes/cardiovascular diseases (CVDs)/metabolic syndrome as a 
group. 
6.3.2.1 Market Size 
The worldwide prevalence of diabetes for all-age groups was estimated to rise from 171 
million (2.8%) in 2000 to 366 million (4.4%) in 2030 (Wild et al., 2004). In 2007, prevalence in 
the US was higher than the global estimate. In the US, 23.6 million (7.8%) people of all ages 
have diabetes. Of these, 17.9 million are diagnosed and 5.7 million are undiagnosed (CDC, 
2009).  
In 2007 in the US, 1.6 million people twenty years and older were newly diagnosed with 
diabetes 50% of which are in the 40-59 age group (CDC, 2009). The mortality rate is difficult to 
obtain because many people are undiagnosed since it is a disease with underlying conditions. 
Therefore, these statistics may be underestimated. In 2005, death certificates indicated that 
diabetes contributed to 233,619 deaths. As such, diabetes was the seventh leading cause of death 
in the US in 2006 (CDC, 2009). In 2007, US $174 billion was spent on diabetes. Direct medical 
costs were US $116 billion and indirect costs were US $58 billion (CDC, 2009).  
6.3.2.2 Competitive Landscape 
The US National Institute of Health (NIH) website lists 2027 open clinical trial studies 
related to diabetes (ClinicalTrials, 2010). For metabolic syndrome, there are 648 open clinical 
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trial studies listed (ClinicalTrials, 2010). For Type 2 diabetes, there are 967 open clinical trial 
studies listed (ClinicalTrials, 2010). There are many treatments already on the market and others 
are in development. These include all types of human therapeutics: small molecules, biologics, 
and emerging RNAi therapeutics. However, most of the treatments available are oral. The 
majority (57%) of adults diagnosed with diabetes take only oral medications, 13% both insulin 
and oral medications, 14% only insulin and 16% take no medications (CDC, 2009). 
In terms of RNAi therapeutics, there are several products in development. This indicates 
higher competition and potential application of RNAi therapeutics in treating diabetes. Firm A 
has a product for diabetic macular edema in Phase II via its partnered program. In addition, there 
are several other products in the discovery and development stage. Firm C has four products in 
their pipeline for Type 2 diabetes: one is in Phase II, one in Phase I and two in the preclinical 
stage. Firm E has one product in the clinical stage for diabetic macular edema. Overall, the 
competition for diabetes is high. 
6.3.3 Cardiovascular Diseases (CVDs) 
Cardiovascular diseases are a group of conditions affecting heart and blood vessels. 
There are many cardiovascular diseases (CVDs). These are widely known as heart attacks and 
strokes. They are often acute and caused by fatty deposits or blood clots that block the blood flow 
to the heart (CDC, 2009). Research for this analysis led to a number of potential gene targets 
related to CVDs.  
6.3.3.1 Market Size 
In 2004, an estimated 17.1 million people died from CVDs worldwide (Rosamond et al., 
2007). This represented 29% of all global deaths making CVDs the number one killer. In the US, 
CVDs affect one in three American adults. In 2004, the estimated prevalence was 79.4 million 
and mortality was 875 thousand (Rosamond et al., 2007). The majority of these deaths were due 
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to coronary heart diseases (7.2 million) and strokes (5.7 million) (Rosamond et al., 2007). Many 
Americans have more than one type of CVDs where an estimated half of those who have them 
are 65 years or older (Rosamond et al., 2007). Since the disease targets elderly, prevalence is 
expected to rise in the future due to the aging population trend. Table 7 summarizes prevalence, 
incidence and mortality of four major categories of CVDs. 
Table 7: Prevalence, Incidence and Mortality of Major CVDs 
 
DISEASE PREVALE
CE I
CIDE
CE MORTALITY 
Total Cardiovascular Diseases 
(CVDs) 
79.4 million - 871.5 thousand 
Coronary Heart Disease 
(CHD) 
15.8 million 
1.2 million 
 
452.3 thousand 
Stroke 5.7 million 700.0 thousand 150.1 thousand 
High Blood Pressure (HBP) 
72.0 million  54.2 thousand 
Heart Failure (HF) 5.2 million  57.7 thousand 
 
 Source: Adapted from information in Heart and Stroke Statistics Report (2007) 
There are many underlying risk factors contributing to CVDs. Some of these are tobacco, 
high blood cholesterol, lack of exercise, obesity, diabetes mellitus, renal disease, chronic kidney 
disease, nutrition, and metabolic syndrome (Rosamond et al., 2007). In 2007, the estimated costs 
for CVDs in the US were US $431.8 billion (Rosamond et al., 2007). In 2004, cancer costs were 
estimated US $190 billion and in 1999 HIV costs were estimated US $28.9 billion (Rosamond et 
al., 2007). Hence, CVDs have the highest economic costs.  
6.3.3.2 Competitive Landscape  
The US National Institute of Health (NIH) website lists 5920 open clinical trial studies 
related to CVDs (ClinicalTrials, 2010). For dyslipidemia there are 233 open clinical trial studies 
and there are 295 open clinical trial studies for atherosclerosis (ClinicalTrials, 2010). In terms of 
RNAi therapeutics, Firm C has five CVD products in development: one is in Phase III, two in 
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Phase I and two in the preclinical stage. While Firm Y’s product shows great potential, there are 
many drugs in development and on the market resulting in high competition. Overall, the 
competition for CVDs is high.  
6.4 Summary: From A Commercial Potential to Strategic 
Options for Firm Y 
 
In this chapter, I assessed a commercial potential of newly identified market 
opportunities for Firm Y based on the business feasibility criteria. This data adds to the final 
comprehensive evaluation of the strategic options for Firm Y that emerged from this analysis. 
The evaluation of the strategic alternatives is partially based on Vining and Meredith metachoice 
evaluation method (2000). These strategic options for Firm Y are: 
(1) First strategic option is status quo. Firm Y should focus only on its current products 
and should not expand its product pipeline.  
(2) Second strategic option is for Firm Y to focus on the liver specific group. Therefore, 
Firm Y should focus on expanding its product pipeline in the direction of the liver 
diseases group that consists of HBV, liver fibrosis and liver cancer (HCC).  
(3) Third strategic option is for Firm Y to focus on a broader group related to the liver. 
Therefore, Firm Y should focus on expanding its product pipeline in the direction of 
liver-associated group that consists of diabetes, CVDs and metabolic syndrome.  
(4) Fourth strategic option is to look for targets not specific to the liver.  
In the next chapter, I analyze these strategic alternatives for Firm Y. The overall 
comprehensive evaluation of the strategic options is based on the integration of all the criteria 
listed in chapter five to ensure suitability for Firm Y. These are: (1) scientific feasibility criteria 
listed in Table 2, (2) business feasibility criteria listed in Table 3, and (3) corporate criteria 
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specific to Firm Y listed in Table 4. The overall comprehensive evaluation leads to the set of 
recommendations for Firm Y.   
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Chapter 7: A COMPREHE
SIVE EVALUATIO
 OF 
THE STRATEGIC OPTIO
S FOR FIRM Y 
In this chapter, I start with the strategic options including the summaries of each 
indication opportunity, and conclude with the overall evaluation that leads to the set of 
recommendations for which strategic option Firm Y should pursue and why.  
7.1.1 The First Strategic Option: Focus on the Current Product 
Pipeline 
 
The first strategic option implies status quo. As a result, Firm Y would focus on 
development of its current products. As such, it would choose not to exercise its option to expand 
its product pipeline. This option would put a high-risk on Firm Y because of the high-risk, high-
failure rate of the DDP. Therefore, failure or underperformance of any of its current products in 
the pipeline could devalue the firm. As such, the first strategic option is high-risk. Overall, it 
would not result in Firm Y’s long-term sustainable growth and competitive advantage within the 
industry. However, it might be a viable option if Firm Y plans to exit via merger or acquisition in 
the near future. As such, the available target worldwide licence agreements would be considered 
as intangible assets adding value to the potential buyer firm.  
7.1.2 The Second Strategic Option: Expanding the Product Pipeline by 
Focusing on the Liver Diseases Group 
 
The second strategic option is the liver specific group of diseases that includes HBV, 
liver fibrosis, and liver cancer, more specifically HCC. In the next sections, I include a brief 
summary of each of the indication opportunities within the group. I follow with the evaluation of 
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the second strategic option as an opportunity for Firm Y based on all the criteria: scientific, 
business, and corporate. The evaluation scores are listed in Table 8. 
7.1.2.1 A Summary of Hepatitis B for Firm Y 
Overall, HBV shows a good potential for Firm Y. It is liver specific. There are examples 
of potential effective treatment strategies using siRNAs in the preclinical studies to treat viral 
infections. Only Firm B is currently working on RNAi therapeutics for HBV. However, the 
product is in the early stage and as such, the FDA experience with the HBV RNAi therapeutics 
might be limited. However, Firm Y already has experience with infectious diseases. In addition, 
HBV has only four genes that significantly reduce the number of potential targets for 
identification and target validation stage in the DDP. However, due to the nature of viral 
infections, RNAi therapeutics for HBV would have to include more than one target. This is to 
ensure complete halting of viral replication. As such, efficacy of treatment could be increased. 
However, the cost of treatment might be higher. In addition, future resistance of the virus to 
RNAi therapeutics can be problematic in terms of the long-term efficacy of the treatment. The 
fact that an effective vaccine is available represents a strategic limitation for Firm Y.  However, 
chronic HBV presents a problem since not many drugs are in development, and those that are on 
the market are not very effective. 
7.1.2.2 A Summary of Liver Fibrosis for Firm Y 
Overall, liver fibrosis shows a medium potential for Firm Y. It is liver specific. There are 
examples of effective treatment strategies in the preclinical and clinical studies using RNAi 
therapeutics. Hence, the FDA is already familiar with the process. However, that the indication is 
not very specific and occurs due to many underlying conditions can be a disadvantage for several 
reasons. First, target identification and optimization might be too complex for Firm Y with its 
limited resources. Second, patient recruitment for clinical trials might be challenging. Third, 
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safety and efficacy might be more difficult to prove due to many underlying conditions. Fourth, 
the need of biopsy for diagnosis could be limiting. Fifth, the fact that the indication is not well 
defined makes it difficult to assess market and commercial potential. On the other hand, the 
broadness of liver fibrosis can lead to a wider application and use of therapeutics for more than 
one indication.  
7.1.2.3 A Summary of HCC for Firm Y 
Overall, HCC shows a good potential for Firm Y. It is liver specific. The complexity of 
the disease adds to the difficulty in assessing market and commercial potential. However, there is 
a significant unmet medical need where RNAi therapeutics can make a real difference. Clinical 
trials might be difficult due to diagnosis and progress monitoring of patients. However, non-toxic 
potential of RNAi therapeutics might lead to accelerated FDA approvals if treatment shows 
significant benefit to the patients compared to the limited treatments currently available. In 
addition, RNAi therapeutics could be used for other liver diseases. Firm A and Firm D are 
developing RNAi therapeutics for liver cancer. Hence, the FDA is already familiar with the 
process. 
7.1.2.4 An Evaluation of the Second Strategic Option 
In terms of scientific criteria, the second strategic group is highly eligible for RNAi 
therapeutics where there is a low to moderate body of evidence for the effective treatment 
strategies in the preclinical and clinical studies. The research for this analysis identified lower, 
but more focused potential gene targets. The liver specificity is high for this strategic option.  
In terms of business criteria, the market size might be smaller for this group; however, 
RNAi therapeutics has an opportunity to address a real unmet medical need compared to current 
conventional methods. As such, Firm Y has a real potential to capture a larger size of this smaller 
market, where if treatments are highly effective Firm Y can charge premium prices for these 
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RNAi therapeutics. In addition, the commercial aspect increases based on the lower competition 
present in this group. Currently, RNAi therapeutics in development are less advanced, however, 
the FDA is somewhat familiar with RNAi therapeutics for this group of indications.  
In terms of corporate criteria, the second strategic option would add to the differentiation 
of Firm Y’s pipeline by expanding into infectious diseases. In addition, it is suitable for 
PLATFORM X’s liver specific capabilities where focus on this group of indications has a higher 
potential to achieve the synergy of target-PLATFORM X product development. The synergy 
refers to a specific delivery of the product to the target site. This is very important in the RNAi 
Therapeutics sector. As such, products that have this target-delivery platform synergy would give 
rise to RNAi therapeutics that treats intended indication with higher effectiveness. Therefore, the 
second strategic option gives Firm Y the opportunity to develop expertise in the liver related 
diseases. This strategic approach can lead to achieving a sustainable competitive advantage based 
on PLATFORM X’s capabilities. This group might have less synergy with current Firm Y’s 
products; however, it is better suited for current and future partnership and exit/integration 
opportunities for Firm Y. 
7.1.3 The Third Strategic Option: Expanding the Product Pipeline by 
Focusing on the Liver-Associated Group 
 
The third strategic option is the liver-associated group of diseases that includes diabetes, 
CVDs, and related metabolic syndrome. In addition, this group has a wide range of risk factors. 
Most of these are common to the indications within the group. Some of them are genetic, lifestyle 
related, or environmental. However, many of these risk factors are preventable with healthier 
lifestyles. In the next sections, I include a brief summary of each of the indication opportunities 
within the group. I follow with the evaluation of the third strategic option as an opportunity for 
Firm Y based on all the criteria: scientific, business and corporate. The evaluation scores are 
listed in Table 8. 
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7.1.3.1 A Summary of Diabetes for Firm Y 
Overall, diabetes shows a low to medium potential for Firm Y. Diabetes is not liver 
specific. There are examples of effective treatment strategies in the preclinical and clinical 
studies using RNAi therapeutics. As such, the FDA is familiar with RNAi therapeutics related to 
diabetes. The potential product might be applicable to treating more than one condition. There 
are quite a few potential targets. However, the high number of potential targets might be costly 
and difficult to identify, optimize, and validate. Diabetes is an indication of many underlying 
conditions and it is highly preventable. The competition for diabetes is high and many 
medications are oral. Firm Y’s RNAi therapeutics would have to be superior to current treatments 
with high potential to treating the unmet medical need. It might be too difficult to make a 
difference on the already saturated market. However, in-depth analysis on the gene level is 
needed to assess current gaps in treatments and if there is potential for RNAi therapeutics, and 
more importantly for Firm Y. However, that is beyond the scope of this project.  
7.1.3.2 A Summary of Cardiovascular Diseases for Firm Y 
Overall, CVDs show a low to medium potential for Firm Y. CVDs are not liver specific. 
There are examples of effective treatment strategies in the preclinical and clinical studies using 
RNAi therapeutics. As such, the FDA is familiar with RNAi therapeutics in regards to CVDs. 
There are quite a few potential targets. In fact, the highest number of potential targets identified 
for this analysis was for the CVDs. However, finding, optimizing, and validating these targets 
might be costly and difficult. CVDs are diseases of many underlying conditions and are highly 
preventable. The competition is even higher than for diabetes where there are many medications 
already available and in development. As such, Firm Y’s RNAi therapeutics product would have 
to have higher effectiveness and treat the disease better than current treatments. As for diabetes, a 
more detailed unmet medical need based on gene analysis still needs to be conducted in order to 
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assess why current medications are not addressing this need. However, that is beyond the scope 
of this project.  
7.1.3.3 An Evaluation of the Third Strategic Option 
In terms of scientific criteria, the third strategic group is moderately eligible for RNAi 
therapeutics, but there is a moderate body of evidence for the effective treatment strategies in the 
preclinical and clinical studies. The research for this analysis identified more, but less focused 
potential gene targets. The liver specificity is low for this strategic option.  
In terms of business criteria, the market size might be larger for this group; however, 
RNAi therapeutics might have a lower opportunity to address a real unmet medical need 
compared to current conventional methods. As such, Firm Y might not have the potential to 
capture a larger size of this larger market. In addition, the commercial aspect for this group 
decreases based on the high competition present in this group. Currently, RNAi therapeutics in 
development is more advanced, hence, the FDA is familiar with RNAi therapeutics for this group 
of indications.  
In terms of corporate criteria, the third strategic option would not add to Firm Y’s 
pipeline differentiation. In addition, it is less suitable for PLATFORM X’s liver specific 
capabilities where focus on this group of indications has a lower potential to achieve the synergy 
of target-PLATFORM X product development. This group has higher synergy with current Firm 
Y’s products. This is an advantage because Firm Y has in-house knowledge in this area. 
However, a disadvantage is that moving further in this direction would result in a less diversified 
product portfolio. This group is considered a worse fit for current and future partnership and 
exit/integration opportunities for Firm Y.  
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7.1.4 The Fourth Strategic Option: Searching Beyond the Liver 
The fourth strategic option considers targets in tissues or organs other than the liver. This 
option would explore PLATFORM Xs delivery capability to other organs. However, that is 
beyond the scope of this project. As such, I do not consider the fourth strategic option in this 
analysis.  
7.2 An Evaluation of Firm Y’s Strategic Options 
In this section, I present the results in Table 8. The table shows all the strategic options, 
evaluation criteria and scores based on the overall integrated analyses conducted so far for this 
project.  
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Table 8: A Comprehensive Evaluation of Strategic Options for Firm Y 
 
GOALS 
(EVALUATIO
 CRITERIA) 
FIRST 
STRATEGIC 
OPTIO
 
SECO
D 
STRATEGIC 
OPTIO
 
THIRD STRATEGIC 
OPTIO
 
SCORI
G (1-5) 
1 is the lowest 
5 is the highest 

O 

EW 
PRODUCTS 
LIVER 
DISEASES 
GROUP 
LIVER-ASSOCIATED 
GROUP 
SCIE
TIFIC FEASIBILITY 
ELIGIBLE FOR R
Ai 1 4 3 
PROOF-OF-CO
CEPT EVIDE
CE 1 3 4 
FOCUSED GE
E TARGET 1 3 2 
LIVER SPECIFICITY 1 4 3 
BUSI
ESS FEASIBILITY 
MARKET POTE
TIAL 1 4 3 
U
MET MEDICAL 
EED 1 4 2 
COMPETITIVE LA
DSCAPE 1 4 2 
FDA EXPERIE
CE WITH R
Ai 
THERAPEUTICS 
1 3 4 
CORPORATE ATTRACTIVE
ESS 
CORPORATE PIPELI
E GROWTH 
(DIFFERE
TIATIO
) 
1 4 2 
SY
ERGY WITH PLATFORM X 2 4 3 
SY
ERGY WITH CURRE
T 
PRODUCTS 
1 3 4 
PART
ERSHIP SY
ERGY 
(CURRE
T) 
2 4 3 
PART
ERSHIP SY
ERGY (FUTURE) 2 4 3 
EXIT/I
TEGRATIO
 
(STRATEGY) 
2 4 3 
TOTAL SCORE 18 52 41 
TOTAL POSSIBLE SCORE 70 70 70 
 
The scoring scheme for the evaluation criteria is from one to five. One is the lowest and 
five is the highest. Hence, the higher the overall score, the better the standing of each of the 
strategic options for Firm Y. For the first strategic option, I assigned one for the first two 
categories, because these were not applicable to the first strategic option as it assumes that Firm 
Y would not expand its product pipeline. In addition, it is worth briefly discussing the scoring 
rationale for criterion number three (focused gene target) and number five (market potential).  
For the number three criterion, the lower the score the more difficult it is to identify the 
target. The number of potential targets is also important. First, many targets get a lower score. 
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Second, targets not related to the liver get a lower score. For example, HBV has a higher score 
because it has four genes and, as such, a lower number of potential targets, and is liver specific.  
For number five criterion, I based the scores on the potential to capture market share. It is 
not based on market size. I consider the potential effectiveness of the treatment developed by 
Firm Y. As such, for the liver diseases group there are not many treatments on the market and 
those that are available are not meeting the medical need. In addition, majority of these 
treatments are not oral. In addition, I considered Firm Y’s organizational capabilities. Would 
Firm Y be able to excel in treating this indication? If yes, I assumed that Firm Y would have a 
higher chance to capture a larger market share of a smaller market. In contrast, the liver-
associated group already has various treatments on the market and many of these are oral 
treatments. Hence, Firm Y would have to compete against intense competition with its 
intravenously administered products. However, the competitive landscape of the second strategic 
group is quite complex and requires resources for a deeper analysis. Thus, the evaluation, 
analysis, and scores are based on limited data and resources available for this project. 
7.2.1 A Summary of the Results of the Evaluation of Potential 
ew 
Markets for Firm Y 
 
Table 8 shows results for the comprehensive evaluation of strategic options for Firm Y. 
The second strategic option focusing on liver diseases has the highest overall score of 52/70. In 
addition, it has the highest score for each section. The score in the scientific feasibility section is 
14/20, 15/20 in the business feasibility section, and 23/30 in the firm’s attractiveness section. To 
summarize, this is because the second strategic option: (1) is specific to the liver, (2) has high 
unmet medical needs, and (3) has synergy potential with Firm Y’s overall organizational 
capabilities mainly PLATFORM X’s capabilities and the firm’s partnerships. 
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The third strategic option with focus on liver-associated diseases has the overall score of 
41/70. The score in the scientific feasibility section is 12/20, 11/20 in the business feasibility 
section, and 18/30 in the firm’s attractiveness section. To summarize, this is because the third 
strategic option: (1) is less specific to the liver, (2) has high competition and high preventability, 
and (3) is lacking synergy potential and attractiveness for Firm Y’s overall organizational 
capabilities mainly PLATFORM X’s capabilities and the firm’s partnerships. In the next chapter, 
I provide Firm Y with the final set of recommendations.  
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Chapter 8: RECOMME
DATIO
S FOR FIRM Y 
8.1 Moving Forward With the Second Strategic Option 
Previous chapters evaluated and assessed the four strategic options based on research and 
analyses conducted. The second strategic option has the highest score. This indicates two 
conclusions: (1) Firm Y should expand its product pipeline and (2) it should do so strategically in 
the direction of the liver diseases group. This is due to PLATFORM X’s core competency to 
deliver to the liver. For the purpose of this analysis, the liver diseases group includes HBV, liver 
fibrosis, and liver cancer (HCC) indications. In addition, I recommend Firm Y focuses on 
infectious diseases, specifically HBV, first and then later expands into HCC since the expansion 
should be based on Firm Y’s organizational capabilities and corporate strategy. This approach 
will allow Firm Y to grow while sustaining its competitive advantage within the RNAi 
Therapeutics sector. In the next section, I highlight potential benefits for pursuing this strategic 
option. 
8.2 Benefits of Focusing on the Liver Diseases Group 
8.2.1 Diversification of Risk With 
ew Products 
Adding new products to Firm Y’s current product pipeline will diversify the risk of 
potential future product failures. The firm is preparing to advance its first product to the planned 
Phase I/II clinical trials where safety and efficacy will be tested. This is an important stage in the 
development of the drug. This product has already been pulled once from Phase I trials in order 
to test it using an improved formulation of PLATFORM X. However, there is a risk that the 
product will not hold to anticipated efficacy. This can devalue the overall potential of the 
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product. In addition, Firm Y’s second product is preparing for Phase I trial. These are important 
milestones for the product development of the firm. As such, this is an appropriate time to start 
advancing new products into the pipeline. These new products would diversify the risk and show 
a long-term growth potential of the firm. 
8.2.2 In Line With the Current Partnerships 
First, Firm Y’s recent partnership will add significant value to having more products in 
its pipeline. It is the multi-year target validation agreement with a Big Pharma firm. Firm Y will 
further gain important knowledge and capabilities in target validation so that it can identify and 
validate targets internally for its own products. 
Second, the two recent accomplishments of Firm Y will add to the synergy with the 
second strategic option. Firm Y published collaborative results showing successful elimination of 
one of the viruses in monkeys (Firm Y, 2009). In continuation to this success, Firm Y signed a 
contract to develop RNAi therapeutics against one of these viruses (Firm Y, 2009). This is 
significant for Firm Y since it further expands its product development capabilities into viral 
infections as well. Thus, Firm Y has experience with products related to “bad’ cholesterol, hence 
CVDs, solid tumours, and infectious diseases. This development is in-line with the second 
strategic option where Firm Y can transfer this knowledge into developing its own antiviral 
product.  
8.2.3 Starting With HBV 
Based on this analysis, I recommend Firm Y pursues HBV for its future product 
development. However, there are some risks and challenges. First, target identification will 
depend on Firm Y’s license agreements with its partner where Firm Y would have to choose 
targets in which its partner is not interested. Second, due to nature of viral infections, Firm Y will 
have to target more than one gene of the virus, and as such, might have to use more than one 
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target per indication. Furthermore, there might be a problem related to future viral resistance. 
Nonetheless, there is a benefit to starting with HBV since it has four genes in its genome, where 
costs associated with identification and validation of targets can be lower. In addition, Firm Y has 
experience in the area of viral infections.  
Targeting liver diseases group can have a good synergy with PLATFORM X’s core 
competency. This potentially results in the development of safer and more efficacious RNAi 
therapeutics treating the disease at its core target organ, the liver. Furthermore, Firm Y can look 
into combinatorial approaches that would target both viral and cellular genes. However, safety is 
a concern because targeting too many genes could trigger an important biological process in the 
host. This would result in side effects and less safe treatments.  
8.2.4 Summary: The Second Strategic Option is a Good Fit for Firm Y 
The second strategic option gives Firm Y a potential of targeting a niche market within 
the broad liver diseases. It has a real potential to address the high-unmet medical need. Firm Y 
has in-house experience within the infectious diseases and oncology sectors, thus HBV and HCC 
are a good fit. Another compelling commercial aspect is that treatments for HCC are limited. 
There is relatively low competition both in the RNAi Therapeutics sector and overall. In addition, 
depending on firm’s exit strategy, the HBV/liver fibrosis/HCC focus has a potential to give Firm 
Y competitive advantage over other firms. Movement towards infectious diseases and HCC 
would make Firm Y a great candidate for a merger or acquisition with other sector leaders or a 
Big Pharma firm which are not developing products for this group of indications.  
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8.2.5 Challenges and Risks Moving Forward With Liver Diseases  
8.2.5.1 Method Limitations 
It should be noted that this analysis and recommendations for new market opportunities 
are based on limited data and resources. As such, Firm Y needs to conduct further analysis. First, 
Firm Y should obtain deeper analysis of each indication on a gene level, and assess RNAi 
therapeutics potential and gaps in available treatments. This is especially important for the liver-
associated group. There are many therapeutics on the market and in development, and yet, 
diabetes and CVDs are leading causes of death. For the purpose of this analysis, I put 
considerable weight on the fact that many risk factors for the liver-associated group are 
preventable. However, as mentioned, the strategic group should be further analysed in terms of 
gene targets. Is there a gene to target by RNAi therapeutics that cannot be targeted with other 
conventional methods, but can meet current unmet medical needs? And if so, does Firm Y have 
organizational capabilities to develop such RNAi therapeutics? Furthermore, each indication 
needs to be analyzed based on internal data of Firm Y, and specifically, its estimated costs of 
drug development and manufacturing.  
Another risk is the grouping of indications presented in this analysis. Firm Y can further 
diversify its portfolio and choose to explore targets in both groups. As such, it might choose to 
develop products for both HBV and Type 2 diabetes. However, further analysis is needed to 
assess this alternative option. 
8.2.5.2 Recommendation Risks 
The primary risk is the fact that the liver diseases group poses limitations due to 
agreements Firm Y has with its partners. Another risk is that, even though it is important to have 
a diversified portfolio, for some firms this is not feasible. Firm Y needs to assess internally its 
ability to expand its pipeline. Also, it should assess how many indications it should pursue at 
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once. As such, Firm Y needs to address questions relevant to its other operations and the 
potential impact of the product pipeline expansion. Moreover, due to its knowledge in CVDs via 
its first product, Firm Y might choose to expand in that direction instead of diversifying into 
infectious diseases. 
8.3 General Recommendations Moving Forward  
PLATFORM X gives Firm Y competitive advantage within the RNAi Therapeutics 
sector. This is evident by its important partnerships gained via out-licensing of PLATFORM X. 
However, Firm Y should broaden the scope of PLATFORM X’s delivery capability beyond the 
liver, enabling it to develop products for more indications and to gain new partnerships. In 
addition, PLATFORM X’s broader application beyond the liver would give it a potential to 
become a delivery standard platform within the RNAi Therapeutics sector. 
The research conducted for this analysis indicates further opportunities for Firm Y in the 
RNAi Therapeutics sector. These are: 
 PLATFORM X can carry nucleic acids other than siRNAs. Firm Y can consider 
emerging opportunities for other nucleic acids, such as miRNAs. These can be explored 
as: (1) new product opportunities and (2) potential new partnerships, which can lead to 
future revenues for Firm Y. 
 
 Firm Y’s manufacturing capabilities cannot be underestimated. Manufacturing can be 
pursued beyond the product development stage of RNAi therapeutics that use 
PLATFORM X. As such, Firm Y should be the main manufacturer for PLATFORM X 
products when they reach the market. Thus, broader manufacturing capabilities can add 
value to Firm Y in the future.  
 
 Firm Y should look for more opportunities and have a greater involvement within the 
local biotechnology community. Firm Y can apply for smaller collaborative research 
government grants. This would allow the firm to leverage on local expertise in areas of 
cancer, infectious diseases, cardiovascular diseases, and diabetes. Furthermore, these 
collaborations can lead to accelerated potential target identification and validation for 
future products.  
 
Firm Y has the needed organizational capabilities to excel in the RNAi Therapeutics 
sector. Analysis for this study shows that Firm Y should add new products to its product 
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development pipeline to showcase long-term growth potential to its shareholders. In addition, this 
analysis indicates that strategic expansion should be in the area of liver specific diseases in order 
to capitalize on PLATFORM X’s core competencies. Firm Y has great delivery system 
PLATFORM X, products in its product portfolio, streamline of important partnerships, and 
manufacturing capabilities. However, to enter new indication markets Firm Y has to ensure that it 
has systems in place necessary for the expansion of its product pipeline. This business strategy, 
in-line with the corporate strategy, will ensure controlled expansion to a more diversified product 
portfolio. As a result, Firm Y will continue to build value for itself and its shareholders. Overall, 
the RNAi Therapeutics is a promising and exciting sector in which Firm Y has an important role.  
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